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Many studies have estimated the treatment effect of different antiretroviral 
therapies (ARTs) on human immunodeficiency virus (HIV) patients’ 
virologic/immunologic outcomes. However, evidence is lacking on how adherence to 
ARTs influences treatment effects.  
The goal of this study is to explore HIV treatment-naïve veterans’ health care 
utilization and to investigate the effect of early adherence on initial viral suppression by 
different regimens.  
A cohort study was conducted on HIV veterans initiating ARTs in 1999-2015. The 
follow-up time was one year since the first fill of base agent (index date). Patients’ health 
care utilization during the follow-up as well as the correlations between initial adherence 
and one-year adherence were estimated. The primary outcome was the first viral 
suppression occurred within thirty to 60 days since the index date. Multiple imputation was 
used to impute the missing value of virologic outcomes. The inverse probability of 
treatment weighting (IPTW) method was applied to estimate the viral suppression rate at 
each specific adherence category for each regimen category. Marginal structural models 
(MSMs) with IPTW were used to estimate the risk of viral suppression in lower-adherence 
categories in comparison to near-perfect adherence level ≥95%. 
Data showed that all patients had at least one follow-up test or visit in the one year. 
The mean of initial adherence to the base agent was 0.84–0.90, depending on the regimens, 
 iv 
 
with unboosted protease inhibitors (PIs) lowest and integrase inhibitors (INSTIs) highest. 
The correlations between initial adherence and thereafter one-year proportion of days 
covered (PDC) were medium, estimated at 0.54–0.63. Lower adherence caused lower viral 
suppression rate, with the association differentiated by the regimen. Patients on INSTIs 
had the highest viral suppression rate, with patients on PIs having the lowest rate. 
Regardless of regimens, the viral suppression rate among patients at initial adherence of 
75-<95% was not statistically different from patients at adherence of ≥ 95%; however, the 
differences might be clinically significant. 
Initial adherence differently influenced the viral suppression rate across different 
regimens. Regardless of regimen categories, no evidence shows 95% adherence threshold 
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1.1 Human Immunodeficiency Virus and  
Immune System Response 
 
The human immunodeficiency virus (HIV) is a virus that can be transmitted via 
bodily fluids by sexual contact, injection drug use, childbirth, breastfeeding, or blood 
transfusion.1 There are two types of HIV infection: HIV-1 and HIV-2. The majority of 
HIV infections are of HIV-1; HIV-2 is prevalent only in western Africa and in 
countries related to western Africa.2 In comparison, HIV-2 has lower transmission risk 
and is less progressive than HIV-1, due to its persistent lower viral loads.  
Once HIV enters the human body, its targets are lymphocytes or T-cells through 
CD4 molecules and chemokine receptors.3 The role of T-cells is to facilitate the body’s 
immunity response to cellular abnormalities and infections.3 If T-cell counts are too 
low, then the immune system cannot fight infections. 3 At the same time, once HIV 
contacts a T-cell, it injects its genetic material into the cell. The proteins on the surface 
of HIV are attached to receptors and co-receptors on the surface of the T-cell, and HIV 
penetrates the cells and releases its ribonucleic acid (RNA) and enzymes into the cell.3 






Therefore, viral loads and CD4 T-cell counts are the best gauge to evaluate the 
level of HIV virus and the response of the immune system to the invading virus, 
respectively. There is an inverse relationship between viral load and CD4 counts. 
During the early HIV infection, HIV RNA can reach the highest level (>100,000 
copies/mL) and CD4 T-cell counts drop sharply before stabilizing at 500-600 
cells/mm3.4,5 Once the initial infection period has passed, viral loads begin to decrease 
and remain at a low level due to the immune system response.6 However, viral loads 
increase over time, since they destroy CD4 cells, which damages the immune system.6 
There is no normal range for viral loads; clinically, the treatment goal is to suppress 
viral load to an undetectable level. The optimal viral suppression is generally defined 
as a viral load persistently lower than 20-75 copies/mL.5  
For adults or adolescents, the normal range of CD4 counts is 500-1500 
cells/mm3.7 It is estimated that an untreated HIV patient’s CD4 T-cell count drops by 
about 45 cells/mm3 every 6 months.4 When the CD4 cell count drops down to 200-500 
cells/mm3, it indicates some damage has occurred in the immune system; when the 
CD4 cell count is below 200 cells/mm3, patients are at high risk of developing an HIV-
related illness.4 It is common to use CD4 counts less than 200 cells/mm3 to determine 
if a HIV-positive patient has progressed to acquired immune deficiency syndrome 
(AIDS).7 CD4 count is also commonly used to determine when to initiate antiretroviral 
therapy (ART). The 2013 World Health Organization (WHO) guidelines recommend 
initiation of ART when a CD4 count drops to ≤ 500 cells/mm3 in all populations, 
including people in low- and middle-income countries.8 The recently issued HIV 





recommend starting ART as soon as possible once the diagnosis of HIV is confirmed.5 
However, the guidelines from European countries suggest initiating ART only among 
patients with a CD4 count of ≤350 cells/mm3. 9,10 Although CD4 count is the major 
factor that is used to decide whether treatment initiation is necessary, some providers 
may decide to start treatment based on viral loads alone.6 
 
1.2 Epidemiology of HIV in the US 
It is estimated that more than 1.2 million people in the United States are living 
with HIV, and about 14% among those are unaware of their infection.11 About 50,000 
and 30,000 people are newly infected with HIV and AIDS, respectively, in the United 
States annually.12 The high-risk groups of HIV infections mainly include homosexual 
and bisexual men and young African-Americans.11 In 2010, men who have sex with 
men accounted for 78% of new HIV infection among males and 63% of al l new 
infections; among new HIV infections of men who have sex with men, half of the 
infections occurred in young African-Americans.11 African-Americans experience the 
highest risk of HIV infection of any racial/ethnical groups. It estimated that African-
Americans, who represented 12% of the US population in 2010, accounted for 44% of 
new HIV infections that year. 11 Hispanics and Latinos also have a relatively higher 
risk of HIV infection than other racial/ethnical groups. In 2010, Hispanics/Latinos 
represented 16% of the US population but accounted for 21% of new HIV infections.11 
However, due to early treatment, the life expectancy of HIV patients has 
improved greatly. On average, life expectancy at age 20 in the US population is 





meta-analysis study was performed for HIV/AIDS to elicit utilities from patients on a 
scale ranging from 0 for death to 1 for perfect health. 14 The authors reported that a 
pooled estimate of utility for AIDS patients, symptomatic HIV patients, and 
asymptomatic HIV patients was 0.70, 0.82, and 0.94, respectively.14 
An ongoing research study by the CDC studied the economic burden associated 
with HIV diagnosis and treatment. They reported that in the health care setting, such 
as emergency departments, primary care settings, and urgent care centers, the cost per 
new diagnosis ranged from $1,900 to $10,000 in 2010 dollars; in the nonhealth care 
setting, such as jails, community-based organizations, and outreach venues, the cost 
per new diagnosis ranged from $2,946 to $30,392 in 2010 dollars.15 The study also 
discovered that the average annual ART treatment cost was estimated to be $23,000 in 
2010 dollars per person, and the lifetime HIV treatment costs was estimated to be 
$379,668 in 2010 dollars.15  
 
1.3 Antiretroviral Agents and Treatment Initiation 
The primary goals of antiretroviral agents for HIV are to control HIV 
replication, restore and preserve the immune system, decrease HIV transmission and 
infections, reduce complications caused by HIV, and improve quality of life and 
survival.16 When initiating antiretroviral regimen for treatment-naïve HIV patients, 
two primary issues need be considered: when to initiate treatment and what regimen 
to initiate. As for when to initiate, there are multiple factors to consider , involving 
both disease and patient factors, which include patient’s pretreatment viral load, CD4 





readiness for treatment and treatment factors should also be considered, including 
patient’s knowledge of treatment and its benefits and risks, patient preferences and 
potential adherence, treatment’s adverse effects and convenience, and drug-drug 
interactions.5,16 
CD4 count is a primary factor to determine when to initiate antiretroviral 
therapy in many countries. However, the US guidelines recommend to start ART as 
soon as possible once the diagnosis of HIV is confirmed, regardless of level of CD4 
counts.5  
Currently, there are 6 classes of ARTs available, including 
nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse 
transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FIs), 
CCR5 antagonists, and integrase strand transfer inhibitors (INSTIs).5 According to the 
guidelines, an initial ART regimen generally consists of two NRTIs in combination 
with an NNRTI, a PI (preferably boosted with ritonavir), an INSTI, or a CCR5 
antagonist (namely maraviroc).5 The regimens for treatment-naïve patients are listed 
in Table 1.1.5 
NNRTI-based regimens have virologic potency and durability in treatment-
naïve patients, but their major disadvantages include the prevalence of NNRTI-
resistant viral strains in ART-naïve patients and the NNRTI’s lower barriers for 
developing drug resistance.5 PI-based regimens, especially for ritonavir (RTV)-
boosted PI-based regimens, also demonstrate virologic potency and durability. 
Compared to NNRTI-based regimens, patients treated with PI-based regimens develop 





high pill burden and high potential for interaction with other medications and food.5 
Among all first-line regimens, both NNRTI-based regimens and PI-based regimens are 
most commonly used among HIV treatment-naïve patients.5 As for INSTI-based 
regimens, the primary disadvantages involve a lower genetic barrier to resistance and 
higher frequency of administration than PI-based regimens.5 As for CCR5 antagonists-
based regimen, patients are more likely to discontinue therapy due to lack of efficacy 
than those treated with PI- or NNRTI-based regimens.5 In the recent two decades, 
fixed-dose combinations of ARTs were developed and approved to help reduce pill 
burden. 
 
1.4 Adherence to Antiretroviral Agents 
The guidelines recommend physicians delay initiating ARTs among patients 
who would potentially have poor adherence, because suboptimal adherence is 
associated with many problems, such as virologic failure, drug-resistance, lowered 
immunity, and increased morbidity and mortality.5 However, there is controversy on 
whether near-perfect adherence (adherence ratio ≥95%) is necessary. Many studies 
found that the response of the HIV virus to ARTs appeared to be linear rather than having 
a threshold.17-34 Some studies found patients at medium adherence level could still achieve 
viral suppression without developing drug resistance.35,36  
However, these studies have limitations. They evaluated association between 
adherence and outcomes, not the causal effect of adherence on outcome. They also simply 
used a cumulative measure for adherence and an end point measure for viral load and CD4 





investigated the effect of early adherence on initial viral suppression, and it remains unclear 
on the association between early adherence and long-term adherent behavioral. 
Furthermore, adherence to INSTI-based regimens were rarely studied in the published 
studies. To fill the existing research gap, the goal of this study was to explore HIV 
treatment-naïve veterans’ adherence, visits and monitoring patterns, and also to investigate 





Table 1.1 Recommended and Alternative Antiretroviral Regimen Options for 
Treatment-Naive Patients1, 2 
 
Recommended Initial ART Regimen Options for All Patients,  




• ATV/r plus TDF/FTC3 
• DRV/r plus TDF/FTC3 
INSTI-Based Regimens: 
• DTG plus ABC/3TC3—only for patients who are HLA-B*5701 negative 
• DTG plus TDF/FTC3 
• EVG/cobi/TDF/FTC—only for patients with pretreatment estimated CrCl ≥ 70 mL/min 
(AI) 
• RAL plus TDF/FTC3 
Additional regimens recommended for patients with preART  
plasma HIV RNA <100,000 copies/mL 
NNRTI-Based Regimens: 
• EFV plus ABC/3TC3—only for patients who are HLA-B*5701 negative 
• RPV/TDF/FTC3—only for patients with CD4 cell count >200 cells/mm3 
PI-Based Regimen:  
• ATV/r plus ABC/3TC3 – only for patients who are HLA-B*5701 negative 
Alternative Initial ART Regimen Options4 
PI-Based Regimens: 
• DRV/r plus ABC/3TC3—only for patients who are HLA-B*5701 negative 
• LPV/r (once5 or twice daily) plus ABC/3TC3—only for patients who are HLA-B*5701 
negative 
• LPV/r (once5 or twice daily) plus TDF/FTC3 
INSTI-Based Regimen: 
• RAL plus ABC/3TC3—only for patients who are HLA-B*5701 negative 
 
1 This table has been updated; please check current guidelines.  
 
2 Key to acronyms: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; ATV/r = ritonavir -
boosted atazanavir; cobi = cobicistat; CrCl = creatinine clearance; DRV/r = ritonavir -boosted 
darunavir; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; FTC = emtricitabine; INSTI = 
integrase strand transfer inhibitor; LPV/r = ritonavir-boosted lopinavir; NNRTI = nonnucleoside 
reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease 
inhibitor; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; TDF = tenofovir disoproxil 
fumarate 
 
3 3TC may be substituted for FTC or vice versa. The following combinations in the recommended list 
above are available as co-formulated fixed-dose combinations: ABC/3TC, EFV/TDF/FTC, 
EVG/cobi/TDF/FTC, LPV/r, RPV/TDF/FTC, and TDF/FTC. 
 
4 Regimens that are effective and tolerable, but that have potential disadvantages when compared 
with the recommended regimens listed above or have less data from randomized clinical trials. An 
alternative regimen may be the preferred regimen for some patients. 
 







Published literature indicates that there is an association between adherence to 
ARTs and patients’ viologic/immunologic outcomes, but little is known about whether 
near-perfect adherence is necessary for patients to achieve optimal 
virologic/immuniologic outcome or if the association differs for different regimens. 
Therefore, this literature review was to summarize what has been found in previous 
studies and to identify the research gap that exists. 
 
2.1 Association between Adherence to ARTs and  
Virologic/Immunologic Outcomes 
 
A systematic review of the published literature evaluated the adherence “threshold” 
assumption. The 95% threshold assumption originated with an observational study of 
unboosted PI by Paterson et al., 30 which reported, in a small cohort of 81 US veterans, that 
among the unreported and presumably very small number of patients with at least 95% 
adherence, a much lower percentage of them experienced virologic failure (22% vs. 55–
82%, p<0.001). However, this finding was descriptive in nature and was unadjusted for 
observation time, baseline viral load and CD4 cell count, race/ethnicity, comorbid 





followed the descriptive findings in their paper, investigators did adjust for each of those 
variables. They conducted a multivariable Cox Proportional Hazards regression model, 
which adjusts for differences in follow-up time, and used adherence as a continuous 
measure, implying that they considered the relationship between adherence and outcomes 
to be linear on the log-hazard scale and not a threshold effect. They reported that, for each 
1% absolute increase in adherence percentage, the risk of virologic failure decreased by a 
relative 3%. Thus, the 95% threshold seems to have been a misappropriated, preliminary 
finding that was subsequently applied as evidence supporting the 95% adherence doctrine 
in later HIV health care practice.  
 
2.1.1 Literature Review Procedures 
A systematic review to evaluate the association between adherence to ARTs 
and virologic/immunologic outcomes was conducted in 2015. The goal was to identify 
and characterize evidence supporting or refuting the claim that highly active 
antiretroviral therapy (HAART)’s efficacy on virologic and immunologic outcomes 
occurs at a 95% adherence threshold. The systematic literature review focused on 
English-language observational studies on HAART adherence that were published in 
January 2000 through 2015. PubMed was searched using the search string 
“Antiretroviral Therapy, Highly Active”[Mesh] AND (“HIV”[Mesh] OR “Acquired 
Immunodeficiency Syndrome”[Mesh]) AND (“Patient Compliance”[Mesh] OR 
“Medication Adherence”[Mesh]) AND (“humans”[Mesh] AND English[lang]) and 
eliminated all articles without abstracts. Five inclusion criteria were involved in this 





the study include adults (18+ years of age)? 3. Did the article report the methods used 
to evaluate HIV antiretroviral adherence? 4. Did the article report descriptive statistics 
for that adherence? 5. Did the study report on an evaluation of the association between 
patient antiretroviral adherence and either virologic or immunologic outcomes? 
 
2.1.2 Literature Review Findings 
A total of 419 citations were identified with the initial PubMed search. After 
abstract, date range, and eligibility criteria were applied, 139 studies (33.2%) were 
deemed to address adherence in the required amount of detail. Of these, 56 (13.4%) 
evaluated the association between patient adherence to ARTs and outcomes of interest. 
During full text review, 4 additional articles that satisfied all eligibility criteria were 
identified from the references.  
The sample sizes of the studied populations ranged from 35 to 6,395 patients: 10 
studies had sample sizes less than 100,17,18,24,30,37-42 24 had sample sizes of 100 to 
299,19,20,22,23,33-35,43-59 7 had sample sizes of 300 to 499,28,36,60-64 10 had sample sizes of 500 
to 999,25,27,29,31,65-70 and 8 had sample sizes of more than 1,000.21,26,32,71-75 Only 4 studies 
included veterans as the target study population,21,22,30,31 and 3 studies included women 
only.19,46,57 In terms of source populations, 20 studies were evaluations of United States 
(US) patients samples, 17-24,30,31,34-36,40-44,57,58 20 were European, 26,27,37-39,46,51,53-
56,59,60,62,63,66,68,69,71,76 8 were Canadian, 25,32,50,61,67,72,74,75 7 were African, 28,29,33,45,47,52,73 4 
were Asian, 48,49,64,70 and 1 was Australian. 65 
In terms of study designs, cohort studies were the most prevalent, with 47 in all, 





cohort studies. 17,18,20,23,26,27,29,30,34,35,37,40,41,43,44,50,51,53,55-58,60,61,65-68,70,71,76 There were also 
10 cross-sectional studies, 24,31,33,42,47,49,59,62-64 and 3 case-control studies.28,38,52 Among the 
cohort studies, 7 studies had a long-term follow-up of at least two years,25,60,65,70,73,75,76 and 
4 studies had varied follow-up time with the median duration longer than two years,32,48,50,72 
13 had a follow-up duration of at least one year, 20,34-36,43-46,51,55,56,61,74 and 1 study had 
varied follow-up time with the median duration longer than one year,69 17 had a follow-up 
duration of at least six months, 17-19,21,23,27,29,37,39-41,53,54,57,58,67,71 and 4 had a short-term 
follow-up less than six months.22,26,30,68 
In terms of the ART regimens evaluated, most studies explored the effects of 
adherence to any antiretroviral agents; however, a total of 12, 9, and 4 studies investigated 
both PI- and NNRTI-based regimens, 20,22,25,26,32,34,43,45,67,72,74,75 only PI-based regimens, 
30,37,40,41,51,55,60,61,68 and only NNRTI-based regimens, 38,47,48,73 respectively. In addition, 1 
study 56 included both NNRTI-based regimens and triple NRTI regimens as the treatments 
of interest. 
A summary of important findings from the studies is given in Table 2.1. Among 
studies that analyzed adherence measured as continuous variables, 20 reported using linear 
assumptions in their evaluations of the relationship between adherence and outcomes. Of 
these, 18 17-34 showed statistically significant results and 2 40,66 did not. Among 48 studies 
that analyzed adherence as a categorical variable, 1817,20,21,25-27,29,35-38,40,41,43,44,60,65,72 
reported a statistically significant effect at some threshold, 4 23,32,55,73 reported an evenly 
distributed dose-response relationship between adherence and outcomes (in other words, a 
dose-response relationship without an obvious threshold), and 5 52,53,56,57,69 reported that 





as a categorical variable, 20 22,24,33,42,45-48,50,51,54,58,59,61,63,64,66-68,74,75 only included 
dichotomized adherence in the analysis, masking any information about whether there was 
a threshold or linear effect.  
In the studies that evaluated multilevel categorical adherence to PIs, 2 26,55 reported 
evenly-distributed dose-response relationships for PI-based regimens and 7 20,27,37,40,41,43,60 
identified a threshold effect at levels ranging from 65.6% to 86%, lower than the 95% 
threshold that is commonly accepted in HIV care practice. For NNRTI-based regimens, 1 
study 73 reported evenly-distributed dose-response effects of adherence on outcomes over 
follow-up durations of three to nine months but showed a threshold effect at 80% adherence 
when follow-up was longer than nine months; 5 other studies 17,26,27,38,43 identified the 
different adherence thresholds, ranging from 49% to 86%, which were lower than the PI 
threshold. Another 2 studies reported an evenly-distributed dose-response association 
between adherence and virologic outcomes32 and between adherence and combined 
virologic/immuniologic outcomes25, respectively, while 8 17,21,23,29,35,36,44,65,72 identified a 
threshold effect with the range of 40%-97%; one 65 of these was at 95% and 3 17,36,44 were 
at 90% adherence thresholds. A single study reported a threshold effect of adherence on 
immunologic outcome at an adherence level of 95%.23  
We found that there was very little in the literature to support the “threshold” 
assumption at 95%. While at an individual level, virologic failure is a dichotomous 
outcome that occurs at many adherence levels lower than 95%, at the population level, 
virologic suppression appears to go up in direct, continuous relationship to adherence. 
Nonetheless, a few studies supported a threshold effect, but most at levels lower than 95%. 





based regimens requiring lower levels of adherence compared to PI-based regimens across 
the board. 
The systematic review also suggested that a lower adherence level would be 
unproblematic with newer drugs, since NNRTIs require lower adherence rate than PIs. 
Another systematic review by Kobin and Sheth has confirmed that newer class ARTs need 
only lower adherence levels to achieve and maintain suppression. 77 They discovered that 
the appearance of potent ARTs (i.e., boosted PIs and NNRTIs) has dropped the required 
amount of adherence since 1990s.  
Based on existing literature, the response of the HIV virus to current HAART 
regimens appears to be linear rather than having a threshold, as has been commonly 
promoted. Furthermore, most HIV-infected patients never approach guideline-
recommended adherence to HAART. 
 
2.2 Limitations of Adherence Studies 
The majority of studies evaluated the association between long-term adherence and 
outcome; however, most of them did not measure adherence, viral load, or CD4 T-cell 
counts as time-dependent variables. Rather, they used a cumulative measure for adherence 
and an end point measure for viral load and CD4 T-cell counts. Without handling time-
dependent confounders, the estimates of the relationship may be biased. Although 1 study 
handled time-dependent confounders, this study did not measure adherence to different 
regimens separately.35  
Since there is complexity to estimate the unbiased long-term adherence effect on 





and how the initial adherence is correlated to the adherence in the long term. Such studies 
are very important and supportive to further understand adherence pattern and the 
mechanism of how adherence influences disease outcomes when time matters.  
Furthermore, INSTI-based regimens, which are preferred to treat HIV treatment-
naïve patients, and recommended by current guidelines, have been rarely studied in the 
published literature to evaluate the association between adherence and outcome. Since 
guidelines recommend physicians consider patients’ compliance when deciding whether 
or not to start HIV treatments and suggest the delay of antiretroviral therapy for those who 
are nonadherent, it is important to understand how adherence to ARTs influences patient 




Table 2.1 Summary of Findings from Systematic Review 
Reference Key information 
Arnsten et al., 




 Correlation coefficients imply a linear relationship. 
 One-day adherence may overestimate adherence because of increased 
medication-taking on the day preceding a clinic or research visit 
 There appears to be high correlation between self-report and MEMS 
adherence. 
 Self-report adherence seems to exaggerate real adherence levels. Patients 
were more likely to self-report a high (>90%) or medium (50–89%) 
adherence level than MEMS adherence measures; however, patients with 
a high or medium self-reported adherence level had lower incidence rate 
of viral suppression than those with the same MEMS adherence level. 
Arnsten et al., 





 Analytic approach implies a linear relationship between adherence and 
outcomes. 
 15% of subjects were antiretroviral naïve. 




 Adherence was used as a continuous variable in the multivariable 
analyses. 
 Improved adherence was statistically significantly associated with viral 
load <400 or <1000 copies/ml. 
 The study population was pregnant women. 





 Patients with adherence level of 0–41%, 42–57%, 58–78%, 79–91%, and 
92–100% had a proportion of 10%, 26%, 34%, 32%, and 57% patients 
achieved viral suppression.  
 It seems that 92% had a threshold effect there. There was no difference 
in adherence of 58–78% and 79–91% on viral suppression. 
Bangsberg et al., 




 The 95% threshold was only true for PI-based regimens, not for NNRTI-
based regimens, and the magnitude of difference between 74–94% and 
95–100% was not that substantial. 
 The link between adherence and outcome was based on the PI or NNRTI 
adherence, not the whole regimen. 





 Correlation statistics imply a linear relationship. 
 PIs looked dramatically superior for patients with high adherence 
(≥77%) but worse for patients with low adherence (<77%).  
 For patients treated with NNRTIs, decreased adherence seemed to be 
associated with slightly reduced viral suppression rate if adherence rate 
was ≥49%. But once adherence rate was <49%, the viral suppression rate 
dropped very quickly. 
 Multivariable models may have been overfitted, since only 54 patients 





Table 2.1 Continued 
Reference Key information 
Bastard et al., 





 95% was used as a threshold to dichotomized adherence; continuous 
adherence was not used in the study.  
 The study did not separate the adherence to PIs and to NNRTIs.  
Braithwaite et 




 Used the 500 copies/mL threshold to define “suppression”. 
 Increased adherence and decline in HIV-RNA appeared to be linearly 
associated. However, there was little difference for single PI, because for 
patients with an adherence level within 80–100%, patients who had a 
higher adherence did not increase decline in HIV-RNA. 
 For all regimen categories, when viral suppression was used as an 
outcome, it seemed that for patients with an adherence level within 80–
100%, patients who had a higher adherence did not have an increased 
rate of viral suppression. 





 The study measured time-dependent adherence, VL, and CD4. 
 For initial adherence, highly adherent was statistically associated with 
virologic suppression and increase of CD4count. This might suggest a 
threshold effect of adherence on virologic and immunologic outcomes. 
 For M12–M36 adherence, moderate and high adherence had similar 
effect on viral suppression, but both were statistically different from 
nonadherence. However M12–M36 adherence cannot predict 
immunologic outcome at all. 
 There was a threshold effect at adherence 80% when follow up time was 
longer than 12 months. The suppression rate among 100%, 80–99%, and 
<80% adherent patient were 64.5–71.3%, 61–66.4%, and 30.4–53.8%. 
Combescure et 




 The study explored the probability that the n+1 viral load would exceed 
50 or 1000 copies/mL when the n previous viral load was <50 copies/mL. 
 After several successive viral loads at < 50 copies/mL, reliability reaches 
approximately 94% with a cutoff of 50 copies/mL, and approximately 
99% with a cutoff at 1000 copies/mL. 
 The reliability increased if adherence was improved.  





 Self-reported adherence was used. Good adherence was measured as 
adherence>90%. 
 Adherence of >90% was independently associated with favorable 




Table 2.1 Continued 
Reference Key information 





 Adherence based on pharmacy record had a threshold effect on 
virological outcome (viral load < 400 copies/mL). When adherence was 
less than 80%, then the percentage of patients with viral load <400 
copies/mL fell below 35%; when adherence was higher than 80%, then 
the percentage was in the range of 53–66%. The similar observation was 
not found for patient-reported adherence. 





 95% was used as a threshold. Adherence was independently associated 
with viral failure. 
Ghate et al., 
2013, Indian J 
Med Res (PMID 
23760381)48 
Key information: 
 Descriptive analysis was for the association between adherence and 
outcome.  
 Adherence >95% was necessary for patients to achieve favorable 
outcome. 
Gross et al., 




 The study did not identify a clear threshold effect for adherence.  
 Patients with greater adherence had a greater likelihood of maintained 
suppression even below the 95% threshold. Incremental increases in 
adherence at levels <95% should be viewed as a worthwhile goal. 
Grossberg et al., 






 Refill-defined adherence performed better than the self-reported 
adherence to predict viral load change. 
 Pharmacy-based refill adherence had linear relationship with viral load. 
Self-report adherence might have threshold association (85% as a 
cutoff). 





 Most patients in the study would fell in the lowest adherence category. 
 For CD4 cell counts, the threshold for diminishing returns was 
adherence=100%; adherence levels >90% were associated with reduced 
efficacy, although there was no significance test of this question. 
 Investigators reported a statistically significant “linear trend” for the 
relationship between adherence and both virologic and immunologic 
outcomes. 
 The study did not adjust for confounding. 
Hong et al., 




 Bivariate analyses were conducted between adherence and virologic 
suppression. 
 Only MPR was found associated with outcome. 
 The threshold of <75% MPR was significantly associated with virologic 
failure ≥5000 copies/ mL at 6 months. This finding suggests that MPR 
may be a useful tool to help identify patients at risk for early virologic 




Table 2.1 Continued 
Reference Key information 
Huong et al., 




 They investigated several measures of self-reported adherence, but none 
of them were associated with risk of virological failure. 






 Regardless of using continuous SPNS score or score categories, SPNS 
was statistically significantly associated with viral load. 





 Threshold effect (≥95%) of adherence on HIV RNA viral suppression 
among injectable drug user. 





 The study used 90% as a cutoff of adherence. The outcome was treatment 
failure including death and viral load >500 copies/mL. 
 For patients with follow-up time longer than 3 years, continuous 
adherence did not reach statistical significance. 
Kuyper et al., 





 The study did not use adherence as a continuous variable. Patients with 
adherence <95% experienced more rapid viral rebound rates. 
Le Moing et al., 





 Self-reported adherence was measured and taking 100% of scheduled 
pills was reported as full adherence.  
 Adherence was only statistically related to early virologic response at 
M4 but not to early immunologic response at M4. 





 Regardless of the regimen received, it seemed that there was a linear 
relationship between adherence immunologic/ virologic responses. 
 95% adherence might only be required for unboosted PI regimen. 
 In patients treated with NNRTI-based regimens, adherence level of 
80%–<95% their outcomes were still good. 
Lima et al., 





 There was no obvious dose-response relationship between adherence and 
risk of viral rebound, after adjusting for duration of suppression. 
 Adherence level of 40% to < 80% was not worse than adherence level of 
80% to <95% according to its effect on virologic rebound. 






 With the increased follow-up duration, the effect size of adherence on 
the change of viral load would also increase. 
 With the increased follow-up duration, the effect size of dose-timing 




Table 2.1 Continued 
Reference Key information 
Lopez et al., 




 In multivariate Cox model, adherence itself was not statistically 
associated virologic failure, but the interaction term of ddI-EC with food 
according to adherence level was statistical significant. In this study, 
adherence at 80% was identified as a cutoff. 
Maggiolo et al., 




 For NNRTI-based regimen, there was a linear relationship between 
adherence and outcome. 
 However, for PI-based regimen, there might be a threshold effect at 
adherence level of 85%. 
Maggiolo et al., 




 There was linear relationship between adherence and viral rebound.  
 However, for single and boosted PI based regimens, 95% threshold 
might be important. 






 Pill count adherence has linear relationship with the risk of virologic 
failure.  
Messou et al., 





 There was a linear relationship between adherence and viral load 
suppression. 
 Compared to adherence of >95%, adherence level of 80–95% was only 
significantly associated with higher chance of virologic failure and wild 
type HIV-1 but not virologic failure and resistance. This indicated that 
80% might be an important threshold of adherence to predict combined 
outcome of viral load and resistance. 
Moore et al., 




 In the study, the researchers did not include continuous adherence as a 
variable, instead they used 90% as a cutoff to dichotomize adherence. 
 The article studied PI-based regimens. 





 In the study, the researchers did not include continuous adherence as a 
variable, instead they used 90% as a cutoff to dichotomize adherence. 
 The article studied PI-based regimens. 






 This is a study about self-reported adherence, but no percentage 
adherence was used.  
 The results based on univatiate analyses. 
Nachega et al., 




 The study was based on NNRTI-based regimens. 
 The dose response relationship between adherence and both viral 




Table 2.1 Continued 
Reference Key information 
Ncaca et al., 




 In the study, treatment interruption might be more important than 
cumulative adherence to predict viral failure. Neither adherence <90% 
nor <95% was associated with increased risk of viral failure compared to 
adherence ≥90% and ≥95%, respectively. 





 In the study, 85% was used a cutoff to dichotomize adherence. However, 
the lower adherence level did not predict viral failure well. It might 
because that sample size was too low to have statistical significant 
results. 
 Only “reporting to stop medication when not feeling well” had a 
statistically significant odds ratio of virologic failure. 
 The study did not adjust covariates. 





 Percentage adherence was not measured.  
 Instead, four questions were used to measure adherence. Median level of 
adherence was selected as a cutoff. Adherence was only associated with 
viral suppression for patients with lower social desirability. 
Parienti et al., 




 All treatments were NNRTI-based. Patients with ≥80% average 
adherence all achieved virologic control. 








 The study measured time-dependent adherence and outcome. The 
studied regimens were boosted PI-based regimens. 
 In longitudinal analyses, adherence measures were significantly 
associated with DVS; however, adherence was not related to virologic 
outcomes in cross-sectional analyses. 
 Timing compliance performed better than other MEMS measures to 
predict DVS. The cutoff to maximize the accuracy of prediction was 
78%. 






 The cutoff of adherence was 90%. The researchers did not use 
continuous adherence as an outcomes. 
  The follow-up time was at least 24 months, which indicates that 
interventions to improve adherence should be prolonged for at least 24 
months. 
Pasternak et al., 




 Compared to the optimal-adherence group, the poor-adherence group 
significantly higher viral load. 
 However, the improving-adherence group did not have the significantly 
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Paterson et al., 




 Each 1-unit increase in adherence was associated with a 3% decreased 
risk of virologic failure, which indicated the linear relationship between 
adherence and outcomes. 
 Doses taken early were not considered “dosing errors”. 
 The study population was mixed incident and prevalent users. 
Perez-Elias et 





 Multivariate analyses indicated that > 90% adherence was statistically 
associated with viral suppression. 
 The study was based on PI-based treatment, and it indicated that 95% 
might not be necessary. 
 Dose response relationship was observed. Compared to indinair, 
nelfinavir performed better when adherence was controlled. 
Perez-Elias et 





 Adherence was not related to the viral suppression in the multivariate 
analysis. 
Pujades-
Rodriguez et al., 





 The relationship between adherence and viral failure was based on a 
univariate analysis. 
 Self-report adherence was measured using 100% as a cutoff. 
Rosenblum et 




 Adherence was measured as a time-dependent variable. Marginal 
structural model was applied in this study.  
 The risk of virologic failure for adherence greater than 50% declines with 
longer duration of continuous suppression. It may suggest that once 
patients achieve viral suppression, suboptimal adherence level ≥50% is 
also acceptable. 
Sethi et al., 2003, 




 No response trend was observed between adherence and viral rebound. 
 Compared to patients with adherence of 100%, only patients with 
adherence of 70–89% had a significant quicker time to have viral 
rebound. 
Sha et al., 2011, 
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Shuter et al., 





 Neither self-reported adherence nor MEMS adherence was associated 
with viral suppression. 
 The study was based on univariate analyses. 
 Self-reported adherence rate of >77.5–92.9% had the highest percentage 
of viral suppression. 
Shuter et al., 




 The study is for evaluating the relationship between adherence to boosted 
PI-based regimen and viral suppression. 
 The study was based on univariate analyses. 
 Adherence of 65.6–85.5% and 85.1–98.7% had almost the same 
percentage of viral suppression. It seems that the effect threshold of 
adherence on viral suppression was at 65.5% in this study. 
Singh et al., 




 Adherence was dichotomized using 90% as a threshold. 
 The association was based on univariate analyses which did not adjust 
for confounding. 






 100% was used as a cutoff. Adherence had significantly higher CD4 cell 
counts in the past 2 days, past week, and past 2 weeks. 
Sumari-de Boer 





 In the study 100% self-reported adherence and 100% pharmacy fill 
adherence were used a cutoff. 
 Nonadherence significantly predicts viral load>40 copies/mL in both 1 
month and 6 month time frames. 
Vallabhanei et 




 Treatment interruption was significantly associated with higher risk of 
virologic failure. 
 The finding was based on univariate analysis. 
VanVaerenbergh 






 Only drug taking adherence and the number of drug holidays reached a 
statistically significant difference. 
 The results were based on univariate analyses. 
Wagner et al., 





 Both patient- and provider- reported adherence predicted continuous 
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 95% was used as a threshold for adherence. Adherence was always 
significantly associated with viral suppression and viral rebound. 
Wood et al., 





 For patients with baseline CD4 count<200 cells/mm3, there was dose-
response between adherence and immunologic response; for patients 
with CD4 count≥200 cells/mm3, there was a threshold effect between 





OBJECTIVES, AIMS, AND SIGNIFICANCE 
 
3.1 Objectives 
Compliance with medical recommendations and drug therapy is thought to improve 
viral suppression and quality of life while reducing drug resistance and mortality risk 
through observational registry data. It remains unknown whether these findings can be 
reproduced in HIV patients’ receiving normal care through the Veterans Health 
Administration (VHA) system in the United States. Many studies focus on the effect of 
initiating HIV therapy and ignore the impact of adherence to treatment. The goal of this 
study was to explore HIV treatment-naïve veterans’ adherence, visits and monitoring 
patterns, and also to investigate the effect of early adherence to ARTs on initial viral 
suppression by different regimens. 
 
3.2 Specific Aims 
The purpose of Aim 1 was to understand ARTs use patterns in a VHA cohort of 
newly initiated HIV patients. Specifically, the study aimed to: 1) describe patient 
characteristics for the study cohort and patient characteristics for subgroups on different 
initiated regimens; 2) identify initial refill patterns and initial adherence to base agent and 




ARTs starting from the second fill of base agent, which will be measured as proportion of 
days covered (PDC) for base agent and complete regimen. 
Aim 2’s purpose was to assess patients’ HIV health care utilization during one year 
since the first fill date of base agent. Specifically, the frequency of visits for HIV care and 
lab testing for HIV treatment for the whole cohort and for the subgroups stratified by 
different characteristics were described. 
Aim 3’s purpose was to evaluate the correlation between the coverage ratio for the 
first fill and one-year adherence after initial fill for both base agent and complete regimen. 
Finally, Aim 4’s purpose was to differentiate patient characteristics at different 
adherence levels and to estimate the unbiased effect of the coverage ratio for the first fill 
of complete regimen on virologic outcome that occurred within thirty to 60 days after initial 
fill date of  base agent. 
 
3.3 Study Significance 
This study not only aimed to address limitations of previous published studies, but 
also had many clinical and scientific significances, as described below.  
 
3.3.1 Clinical Significance 
In the published literature, there was a lack of studies to describe physicians’ 
prescribing habits, for example, who were more likely to prescribed NNRTI vs. boosted PI 
regimens. For the initial regimen, many questions remained, such as what patient adherence 
to the first fill would be and if patients who started with some regimens would have higher 






3.3.2 Scientific Significance 
It remained unknown how HIV patients receive normal care through the VHA 
system. Aim 2 explored this issue. Missing values or censoring issues was another critical 
problem in the observational study but was often neglected by researchers. If missing 
values could not be handled appropriately (i.e., just simply excluding them from the study), 
then it would incur selection bias. In this study, patients who had missing data of virologic 
outcomes were distinguished from patients who were less likely to be lost to follow-up.  
Previous study discovered that patient baseline characteristics alone could not 
predict a veteran’s adherence to ARTs.78 The current study evaluated the correlation 
between initial adherence and one-year adherence to see if the long-term adherence would 
be predictable according to the initial adherence.  
Many published studies made contributions to understanding the association 
between adherence and health outcomes, but rare studies evaluated the causal effect of 
adherence to ARTs on virologic outcome. Without taking patients’ probability of different 
adherence levels into account and handling selection biases, the estimates of the effect of 
adherence on outcome might be biased. Published studies also rarely compared the effect 
of adherence on virologic outcome across different regimens. For example, INSTI-based 
regimens, the preferred regimens to treat HIV treatment-naïve patients and recommended 
by current guidelines, were rarely studied in the published literature. All these questions 
will be addressed in this study. MSMs were applied by adjusting inverse probability 




confounding bias and selection bias to result in an unbiased causal effect estimate. This 
approach has evidenced that IPTW can create a pseudo-population where exposure and 







4.1 Study Design 
4.1.1 Study Time Frame 
This was a nationwide, historical cohort study on antiretroviral-naïve patients 
with incident HIV infection initiating ARTs in the VHA system between January 1, 
1999, and December 31, 2015. The follow-up time was one year from the first fill of 
base agent; specifically, for estimating the effect of initial adherence to ARTs on 
virologic outcomes, the follow-up time was 60 days since the first fill of base agent. 
The first fill date of base agent was defined as index date in this study. 
 
4.1.2 Data Source 
The data source for this study was from VHA databases, which contain data on 
utilization (pharmacy records, inpatient and outpatient encounters); clinical 
parameters (vital signs, laboratory results, radiology reports, etc.); and patient 
eligibility/demographics (age, sex, race/ethnicity). The analytic dataset will be created 
from the Medical SAS (MedSAS), Decision Support System (DSS), and Corporate 
Data Warehouse (CDW) datasets. The MedSAS datasets provide national 




MedSAS datasets contain procedure and diagnosis codes as well as inpatient and 
outpatient pharmacy data. The DSS datasets are comprised of longitudinal inpatient 
and outpatient clinical data. The DSS datasets contain laboratory data, including HIV 
viral load and CD4 cell counts, as well as pharmacy prescription data. The CDW 
datasets contain both clinical and administrative data. The CDW contains information 
about inpatient and outpatient visits including procedure and diagnosis codes, vital 
signs, and outpatient pharmacy data. 
 
4.1.3 Study Population 
 The study cohort was defined as the VA patients with HIV-1 or AIDS identified 
by using the International Classification of Diseases Version 9th (ICD-9) codes of 042 
or V08 from national VHA databases. Patients were included if satisfying the 
following inclusion/exclusion criterion: 1) having at least one ICD-9 code of HIV-1 or 
AIDS 042 or V08; 2) being an adult (18 years or older) at ARTs initiation; 3) receiving 
ARTs consisting of three or more antiretroviral medications including one of base agent of 
PIs, NNRTIs, or INSTIs; 4) having virologic and immunologic lab tests before the index 
date; and 5) having viral load reading before the index date. Patients were excluded if they 
had any evidence showing they would be treatment-experienced.21 Evidence included: 1) 
viral load was less than 500 cells/mL any time before ARTs initiation; 2) initiated regimens 
included 5 or more agents or used a regimen containing 2 base agents (“5 or more agents” 
defined as there are 4 or more antiretroviral agents filled within ±15 days of the first fill of 
base agent; “2 base agents” defined as there was another base agent filled within 15 days 




as no antiretroviral agent filled within ±30 days of the first fill of base agent; 4) received 
any antiretroviral agent earlier than 30 days before the first fill of base agent; or 5) the first 
fill of base agent was not 30 days of supply.  
 
4.2 Variable Definition and Measurements 
4.2.1 Exposure and Treatment Variables 
The primary exposure variables were initial adherences, measured as the coverage 
ratio for the first fill of base agent and of complete regimen, respectively. Before estimating 
primary exposure variables, the relevant treatment variables were defined as follows. 
The base agent variable was classified as unboosted PI, boosted PI, NNRTI, and 
INSTI, which was the same as the classification for the complete regimen. To differentiate 
unboosted PI and boosted PI, boosted PI was defined as the case that a patient has a fill of 
ritonavir within ±3 days of the first fill of a PI; otherwise, it was defined as unboosted PI. 
ARTs discontinuation was defined as when that patient did not have a second fill of base 
agent within 60 days after the index date, since the days of supply for the first fill of base 
agent was 30 days. Switching was defined as when patients changed their base agent from 
one class to another.  
The initial coverage ratio (ICR) for the first fill of base agent (BA) was calculated 




𝐷𝑎𝑦𝑠 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑖𝑛𝑑𝑒𝑥 𝑑𝑎𝑡𝑒 𝑎𝑛𝑑 𝑡ℎ𝑒 𝑠𝑒𝑐𝑜𝑛𝑑 𝑓𝑖𝑙𝑙 𝑑𝑎𝑡𝑒 𝑜𝑓𝑏𝑎𝑠𝑒 𝑎𝑔𝑒𝑛𝑡 
𝑜𝑟 𝐷𝑎𝑦 60 𝑖𝑓 𝑛𝑜 𝑠𝑒𝑐𝑜𝑛𝑑 𝑓𝑖𝑙𝑙  
 .                                                                                                                                          
(4.1) 




the first fill of complete regimen (CR) was calculated according to the formula: 
 
𝐼𝐶𝑅𝐶𝑅 =
𝐷𝑎𝑦𝑠 𝑓𝑜𝑟 𝑐𝑜𝑚𝑝𝑙𝑒𝑡𝑒 𝑟𝑒𝑔𝑖𝑚𝑒𝑛 𝑎𝑣𝑎𝑖𝑙𝑎𝑏𝑙𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑝𝑒𝑟𝑖𝑜𝑑 𝑑𝑒𝑓𝑖𝑛𝑒𝑑 𝑖𝑛 𝑡ℎ𝑒 𝑑𝑒𝑛𝑜𝑚𝑖𝑛𝑎𝑡𝑜𝑟 
𝐷𝑎𝑦𝑠 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑖𝑛𝑑𝑒𝑥 𝑑𝑎𝑡𝑒 𝑎𝑛𝑑 𝑡ℎ𝑒 𝑠𝑒𝑐𝑜𝑛𝑑 𝑓𝑖𝑙𝑙 𝑑𝑎𝑡𝑒 𝑜𝑓 𝑏𝑎𝑠𝑒 𝑎𝑔𝑒𝑛𝑡 
𝑜𝑟 𝐷𝑎𝑦 60 𝑖𝑓 𝑛𝑜 𝑠𝑒𝑐𝑜𝑛𝑑 𝑓𝑖𝑙𝑙  
 . 
(4.2) 
The complete regimen was defined as one base agent plus at least two other NRTIs. 
The thereafter one-year adherence to ARTs was measured using the proportion of 
days covered (PDC) approach. The thereafter one-year PDC for BA was calculated as: 
 
𝑃𝐷𝐶𝐵𝐴 =
𝐷𝑎𝑦𝑠 𝑤ℎ𝑒𝑛 𝑏𝑎𝑠𝑒 𝑎𝑔𝑒𝑛𝑡 𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑖𝑛 1 𝑦𝑒𝑎𝑟 𝑠𝑖𝑛𝑐𝑒 𝑠𝑒𝑐𝑜𝑛𝑑 𝑓𝑖𝑙𝑙 𝑜𝑓 𝑏𝑎𝑠𝑒 𝑎𝑔𝑒𝑛𝑡
𝐷𝑎𝑦𝑠 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑡ℎ𝑒 𝑠𝑒𝑐𝑜𝑛𝑑 𝑓𝑖𝑙𝑙 𝑑𝑎𝑡𝑒 𝑜𝑓 𝑏𝑎𝑠𝑒 𝑎𝑔𝑒𝑛𝑡 𝑎𝑛𝑑
 𝑡ℎ𝑒 𝑒𝑛𝑑 𝑜𝑓 1−𝑦𝑒𝑎𝑟 𝑓𝑜𝑙𝑙𝑜𝑤−𝑢𝑝  
.  
(4.3) 
The thereafter one-year PDC for CR was calculated as: 
 
𝑃𝐷𝐶𝐶𝑅 =
𝐷𝑎𝑦𝑠 𝑤ℎ𝑒𝑛 𝑐𝑜𝑚𝑝𝑙𝑒𝑡𝑒 𝑟𝑒𝑔𝑖𝑚𝑒𝑛 𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑖𝑛 1 𝑦𝑒𝑎𝑟 𝑠𝑖𝑛𝑐𝑒 𝑠𝑒𝑐𝑜𝑛𝑑 𝑓𝑖𝑙𝑙 𝑜𝑓 𝑏𝑎𝑠𝑒 𝑎𝑔𝑒𝑛𝑡
𝐷𝑎𝑦𝑠 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑡ℎ𝑒 𝑠𝑒𝑐𝑜𝑛𝑑 𝑓𝑖𝑙𝑙 𝑑𝑎𝑡𝑒 𝑜𝑓 𝑏𝑎𝑠𝑒 𝑎𝑔𝑒𝑛𝑡 𝑎𝑛𝑑 
𝑡ℎ𝑒 𝑒𝑛𝑑 𝑜𝑓 1−𝑦𝑒𝑎𝑟 𝑓𝑜𝑙𝑙𝑜𝑤−𝑢𝑝  
. 
(4.4) 
If patients switched regimen class, then the observations at the switch date were censored. 
 The ICRs and PDCs were measured as continuous variables. For specific aims, 
these were transformed into binary variables using different thresholds or into categorical 







4.2.2 Outcome Variables 
The primary outcome was that first viral suppression occurred within thirty to 
60 days after the first fill of base agent. The HIV treatment guidelines did not provide 
a specific definition for viral suppression. But the guidelines recommended to target a 
treatment goal of achieving an undetectable level of viral load, defined as <400 
copies/mL in the guidelines of 1999 and <50 copies/mL since 2000.80 It was also 
common to use ≥200/mL copies to define viral failure.80  In this study, viral 
suppression was defined as HIV-1 RNA <400 copies/mL if test year was 1999 and 
HIV-1 RNA <50 copies/mL if test year was 2000 or after. In order to get the robust 
adherence effect estimate on virologic outcomes, sensitivity analyses for evaluating 
initial adherence effect on suppressing viral load to <50 copies/mL, < 200 copies/mL, 
and < 400 copies/mL were also conducted. 
Since CD4 count is not responsive in such a short time period, thirty to 60 days, 
immunologic response was not considered in this study. 
 
4.2.3 HIV Health Care Utilization Variables 
 Health care utilization at the individual level was estimated, including HIV 
office visits, length of stay (LOS) for hospitalization, viral load test frequency, and 
CD4 count test frequency during the one-year period after the index date.  
 
4.2.4 Confounders and Other Covariates 
 Antiretroviral regimens with their relevant characteristics, including efficacy, side 




also risk factors related to virologic outcomes. However, they were not on the causal 
pathway between adherence and outcome. This indicated that regimens and their 
characteristics were important confounders, which made causality of initial adherence on 
virologic outcome complex. Therefore, this study was based on the subgroup of each 
specific regimen category, which negated the need to consider characteristics as a 
confounder. 
As shown in Figure 4.1, confounders associated with initial adherence and virologic 
outcomes that were measured in this study included patient demographics (age, gender, 
and race/ethnicity), baseline HIV disease severity (baseline viral load, baseline CD4 count, 
and opportunistic infection, as defined in Table 4.1, and AIDS defined in Table 4.2), 
baseline overall health status (Deyo-adapted Charlson Comorbidity Index [CCI]), and HIV 
health care utilizations (length of stay [LOS], viral load test frequency, CD4 count test 
frequency, number of HIV office visits) during exposure period.   
Other covariates include social economic status (SES), pill burden, and specific 
comorbid conditions. The specific comorbid conditions were defined in Table 4.3. 
All variables with the anticipated variable formats were listed in Table 4.4. 
 
4.3 Data Analyses 
4.3.1 Data Analyses for Aim 1 
 Patient baseline characteristics including age, gender, race/ethnicity, 
socioeconomic status (SES), viral load, CD4 counts, initiated regimen, pill burden, Deyo-
adpated CCI, and comorbid conditions were summarized for the entire cohort. Mean and 




were calculated for categorical variables. 
 Characteristics between patients initiated on different regimens were compared. 
Since there were four treatment groups to compare, one-way analysis of variance 
(ANOVA) tests were used for continuous variables regardless of data distribution, because 
one-way ANOVA is considered a robust test against the normality assumption. As for 
categorical variables, a Chi-square test or Fisher exact test were to make comparisons 
between groups, depending on whether the expected number for each cell of the variable 
is >5. 
 The proportion of patients who discontinued initiated regimen with 95% confidence 
interval of proportion was calculated for each initiated regimen category. For patients who 
discontinued regimen, their initial coverage ratio of base agent (ICRBA) was automatically 
calculated as 50%, because 30 days of supply were regarded to cover 60 days, which was 
the longest follow-up time that we measured for Aim 4. The mean and STD of ICRBA and 
initial coverage ratio of a complete regimen (ICRCR) for each initiated regimen category 
were calculated. The number and proportion of each class of ICRBA and ICRCR were also 
calculated. 
 The proportions including 95% confidence interval of patients who switched 
regimen category within one year from index date were calculated for each initiated 
regimen category. Mean, STD, and median for days gap between index date and date when 
patients switched initiated regimen category were also calculated. Switching pattern was 
displayed as proportion of patients who switched from a specific regimen category to 
another. 




proportion of days covered of a complete regimen (PDCCR) at individual level were used 
for analyses in Aim 3. 
 
4.3.2 Data Analyses for Aim 2 
 Box and Whisker Plots were drawn for comparing the one-year HIV office visit 
frequency, LOS, viral load test frequency, and CD4 count test frequency among subgroups 
stratified by different categorical variables including initiated regimen, age, race/ethnicity, 
SES, baseline viral load, baseline CD4 count, and Deyo-adapted CCI. 
 
4.3.3 Data Analyses for Aim 3 
 Pearson Correlation was calculated between ICRBA and ICRCR, ICRs and 
thereafter one-year PDCs for each initiated regimen category. The proportions of patients 
at each specific ICRCR category ≥95%, 75–<95%, or <75%) moving to specific thereafter 
one-year PDCCR category (≥95%, 75–<95%, or <75%) were also calculated. Figures were 
drawn to show adherence change pattern by initiated regime. Proportions of patients at 
ICRCR of ≥95%, 80–<95%, 65–<80%, 50–<65%, and <50% moving to specific thereafter 
one-year PDCCR category were displayed in the figure for each initiated regimen category. 
For each regimen category, Kappa coefficient between the ICRBA and one-year PDCCR 
was also calculated. 
 
4.3.4 Data Analyses for Aim 4 
 The analyses for Aim 4 were the core part of this project. First, patients’ baseline 




and low: <75%) for each initiated regimen category via presenting mean with STD for 
continuous variables and number with proportion for categorical variables.  
Second, patients who had virologic outcome data within thirty to 60 days after 
index date were compared to those who do not. Since there were only two groups, t-test 
was used to compare continuous variables, and Chi-square test was used for comparing 
categorical variables. 
Third, data were imputed for patients who had missing virologic outcomes via 
multiple imputation methods to impute log value with base 10 of absolute viral load. In 
order to maximize the accuracy for imputing outcome, imputation was completed for each 
specific initiated regimen category by comparing two different imputation methods 
including monotone regression and Markov chain Monte Carlo (MCMC) method. The 
imputed outcome distribution derived from the two methods was compared with outcome 
distribution from the complete cases to identify the imputed data from one method which 
were more similar to the distribution of complete cases. The imputation model inputs were 
all variables that occurred before the outcome, including initiated pill burden, ICRCR, age, 
gender, race/ethnicity, SES, baseline viral load, baseline CD4 count, Deyo-adapted CCI, 
AIDS, opportunistic infection, specific comorbid conditions, discontinuation indicator, 
switch indicator, time to switch, viral load test frequency, CD4 test frequency, LOS, HIV 
office visit frequency, death within 60 days after index date, and index year.  
Fourth, after the imputation, the crude viral suppression rate at different ICRCR 
category was compared based on completed cases and imputed data. Viral suppression rate 
among 4 groups were also compared (group 1: patients who did not discontinue and had 




missing outcome; group 3: patients who discontinued but had virologic outcome; and group 
4: patients who discontinued and had missing outcome) based on the imputed date. 
Fifth, the IPTW method was used to address confounding bias in this study. There 
were two types of categorical initial adherence variables: dichotomous and multilevel.  
For dichotomous, the IPTW for each individual patient was calculated based on the 
following formula79,81,82: 
 
Numerator of IPTW: Pr (𝐴 = 𝑎𝑖| 𝑉 = 𝑣𝑖) =𝛽1* 𝑉, 
Denominator of IPTW: Pr (𝐴 = 𝑎𝑖| 𝑉 = 𝑣𝑖 , 𝐿 = 𝑙𝑖) =𝛽1* 𝑉 + 𝛽2* 𝐿, 
(4.5) 
where i represents subject i; A is initial coverage ratio indicator (0 inadherent, 1 adherent); 
a is observed initial coverage ratio indicator; L is confounders; V is patient baseline 
characteristics except for confounders. 
For multilevel one, the IPTW for each individual patient was calculated based on 
the following formula79,81,82: 
 
Numerator of IPTW: Pr (𝐴 =  𝑎𝑑ℎ𝑒𝑟𝑒𝑛𝑐𝑒 𝑐𝑎𝑡𝑒𝑔𝑜𝑟𝑦 𝑗 | 𝑉 = 𝑣𝑖) = 𝛽1* 𝑉, 
Denominator of IPTW: Pr(𝐴 =  𝑎𝑑ℎ𝑒𝑟𝑒𝑛𝑐𝑒 𝑐𝑎𝑡𝑒𝑔𝑜𝑟𝑦 𝑗 | 𝑉 = 𝑣𝑖 , 𝐿 = 𝑙𝑖) = 𝛽1* 𝑉 + 
𝛽2* 𝐿, 
(4.6) 
where i represents subject i; j is coverage ratio category: j = 1, 2, 3 with 1 = “≥95%”, 2 = 
“75–<95%”, 3 = “<75%”, and we use 1 as the reference group; A is initial coverage ratio 




characteristics except for confounders. 
Sixth, viral suppression rate was calculated for each adherence group based on 
pseudo-population after weighting IPTW, and MSMs were calculated to estimate 
adherence effects on virologic outcomes.  
For each initiated regimen category, confounders between adherence groups 
(inadherent vs. adherent; ICRCR ≥95% vs. 75-<95% and ICRCR ≥95% vs. <75%) were 
compared before and after applying IPTW via using absolute standardized difference 
estimate (0.1 as reference value). For each initiated regimen category, viral suppression 
rate was calculated for each adherence group after weighting IPTW. For each initiated 
regimen category, adherence effect on virologic outcomes was estimated via MSMs 
models. 
When adherence variable was dichotomous one, then the model was  
 
F(p(Y|V, L))= a*𝛽1 + V*𝛽2 (with weighting IPTW), 
(4.7) 
where Y is viral suppression outcome, V is baseline covariates, L is confounders, a is binary 
adherence, and F is the function (logistic regression to estimate odds ratios in this 
study).79,81,82 
When adherence variable was multilevel one, then the model was  
 
F (p(Y|V, L))= 𝑎1*𝛽11 +𝑎2*𝛽12 +𝑎3*𝛽13 +  V*𝛽2 (with weighting IPW), 
(4.8) 




𝑎1=1 if ICRCR ≥95% and 0 otherwise, 𝑎2=1 if ICRCR 75-<95% and 0 otherwise, 𝑎3=1 if 
ICRCR <75% and 0 otherwise, and F is the function (logistic regression to estimate odds 
ratio in this study). 79,81,82 
Seventh, in order to obtain robust results, sensitivity analyses were conducted with 
multiple ways: 1) applying IPTW approach and building MSMs model based complete 








Table 4.1 ICD-9 Diagnosis Codes for Opportunistic Infections According to the Center 
for Disease Control and Prevention (CDC) Definition83 
 
Comorbidity ICD-9 Code(s) 
Pneumocystis jirovecii pneumonia 136.3 
Toxoplasmosis of brain, onset at age >1 month† 130.0 




Mycobacterium avium complex or Mycobacterium 
kansasii, or other species; disseminated or 
extrapulmonary 
031.XX 
Mycobacterium tuberculosis of any site, pulmonary, 
disseminated, or extrapulmonary 
010-018 
Bacterial pneumonia 481, 482.XX 
Bartonellosis 088.0 
Syphilis 091.XX, 092.X, 093.XX, 
094.XX, 097.X, 096 
Mucocutaneous candidiasis 112.0, 112.2, 112.3, 112.4, 
112.5, 112.8X, 112.9 
Cryptococcosis, extrapulmonary 321.0 
Histoplasmosis, disseminated or extrapulmonary 115.XX 
Coccidioidomycosis, disseminated or extrapulmonary 114.1, 114.2, or 114.3 
Aspergillosis 117.3, 484.6, 518.6 
Cytomegalovirus 078.5 
Herpes simplex virus disease 054.XX 
Varicella zoster virus disease 053.XX 
Human papillomavirus disease 079.4, 795.05, 795.09, 795.15, 
795.19 
Hepatitis B infection 070.2X, 070.3X 
Hepatitis C infection 070.41, 070.44, 070.51, 
070.54, 070.7X 
Progressive multifocal leukoencephalopathy 046.3 
Malaria 084.X 
Leishmaniasis 085.X 







Table 4.2 ICD-9 Diagnosis Codes for AIDS Conditions According to the Center for 
Disease Control and Prevention (CDC) Definition 84 
 
Comorbidity ICD-9 Code(s) 
Candidiasis of bronchi, trachea, or lungs 112.4 
Candidiasis of esophagus 112.84 
Cervical cancer, invasive 180.X 
Coccidioidomycosis, disseminated or extrapulmonary 114.1, 114.2, 114.3 
Cryptococcosis, extrapulmonary 321.0 




Herpes simplex: chronic ulcers or bronchitis, 
pneumonitis, or esophagitis 
054.XX 
Histoplasmosis, disseminated or extrapulmonary 115.XX 
Isosporiasis 007.2 
Kaposi sarcoma 176.XX 
NonHodgkin’s Lymphoma, including Burkitt’s, 
immunoblastic, or primary of brain (or equivalent 
term) 
200.XX, 202.0X, 202.1X, 
202.2X, 202.7X, 202.8X, 
204.1X 
Mycobacterium avium complex or Mycobacterium 
kansasii, or other species; disseminated or 
extrapulmonary 
031.XX 
Mycobacterium tuberculosis of any site, pulmonary, 
disseminated, or extrapulmonary 
010-018 
Pneumocystis jirovecii pneumonia 136.3 
Pneumonia, recurrent V12.61 
Progressive multifocal leukoencephalopathy 046.3 
Salmonella septicemia, recurrent 003.1 
Toxoplasmosis of brain, onset at age >1 month† 130.0 







Table 4.3  List of Comorbid Conditions with ICD-9-CM Codes 
Comorbid Condition ICD-9-CM Codes 
Cancer 140-175, 177-239 




Ischemic heart diseases, angina 401-414 
Cardiac insufficiency 428-429 
Heart valve diseases 424 
Cerebrovascular disease 430-438 
Chronic obstructive pulmonary 
disease 
491.1, 491.20, 491.21, 491.9, 496, 492.0, 492.8 
Osteoarthritis 715-716 
Chronic anemias, autoimmune, 
hemolytic 
280, 281, 282.0, 283-4, 285.0 
Renal insufficiency 585-6 
Depression 296.2X, 296.3X, or 296.82 
Schizophrenic disorder 295.XX 
Psychotic 298.8, 297.3, 293.81, 293.82, 298.9 
Alcohol abuse 305.0X, 303.0, 303.9, 291.XX 
Drug abuse 292.XX, 304.XX, 305.XX 
Hepatitis B Infection 070.2X, 070.3X 






Table 4.4 Variables with Anticipated Variable Formats 
Variables Variable Format 
Treatment Variables 
Regimen/Base agent 
Categorical (Unboosted PI, Boosted PI, NNRTI, 
INSTI) 
Discontinuation Dichotomous (yes or no) 
Switch Dichotomous (yes or no) 
Exposure Variables 
ICACA 
Ratio; Categorical based on distribution; 
Dichotomous (using different threshold at 95%, 
90%, 85%, 80%, 75%) 
ICACR 
Ratio; Categorical based on distribution; 
Dichotomous (using different threshold at 95%, 
90%, 85%, 80%, 75%) 







Health Care Utilization Variables 
HIV office visit frequency 
in one year 
Count 
LOS in one year Count 
Viral load test in one year Count 
CD4 count test in one year Count 
Outcome Variables 
Viral suppression  (viral 
load <50 copies/mL) 
Dichotomous (yes or no) 
Viral load <200 copies/mL Dichotomous (yes or no) 











Table 4.4 Continued 
Variables Variable Format 
Confounders 
Age 
Continuous or categorical (18–35, 36–50, 51–65, 
>65) 
Gender Dichotomous (male or female) 
Race/Ethnicity 
Categorical (White, African-American, Hispanic, 
others, and unknown) 
Baseline viral load 
Continuous or categorical (<10,000, 10,000–
<50,000, 50,000–<100,000 100,000–<500,000, 
≥500,000) 
Baseline CD4 count 
Continuous or categorical (<200, 200–499, ≥500, 
and unknown) 
AIDS Dichotomous (yes or no) 
Opportunistic infection Dichotomous (yes or no) 
Deyo-adapted CCI Continuous or categorical (0, 1–2, ≥3) 
LOS during exposure 
period 
Count 
HIV office visit frequency 
during exposure period 
Count 
Viral load tests during 
exposure period 
Count 




Social Economic Status Categorical based on distribution 
Comorbid conditions 
Dichotomous (yes or no) for each specific comorbid 
condition 
Pill burden (single pill per 
day) 














5.1 Results for Aim 1 
5.1.1 Cohort Selection 
A total of 53,427 veterans with at least one diagnosis of HIV-1 or AIDS from 1999 
to2015 were identified from the VHA databases, and of those, 34,598 patients were treated 
with ARTs. After executing inclusion/exclusion criteria, a total of 10,274 veterans 
remained in the final cohort. The detailed process of selecting the cohort is shown in Figure 
5.1. 
 
5.1.2 Cohort Characteristics 
As shown in Tables 5.1 and 5.2, the cohort were relatively young with a mean age 
of 47.3 years old; the majority were younger than 65 years old at baseline. More than half 
were African-Americans, and about 29% were whites. A total of 36.6% veterans reached 
a very high level of viral load ≥100,000 copies/mL when they initiated the ARTs. About 
9.3% veterans initiated the ARTs with a higher than normal (≥500 cells/mL) CD4 count 
level. Among the cohort, 17.7% and 25.3% patients had AIDS conditions and opportunistic 
infections at the baseline, respectively. There were 976 (9.5%), 2291 (22.3%), 6,374 





INSTIs, respectively. One-third of patients were treated on single-pill ARTs. About 44.2% 
patients had no comorbid conditions. The most frequent comorbid conditions were drug 
abuse, ischemic heart disease, alcohol abuse, and hypertension, with the prevalence being 
48.6%, 30.1%, 29.6%, and 28.6%. 
 Baseline characteristics among patients initiated with different regimens were also 
analyzed (Table 5.3). Patients initiated with boosted PIs had older mean age compared to 
the others; however, patients on INSTIs had the highest proportion of elderly aged over 65 
year old. Whites were more likely to be treated on INSTIs, while African-Americans were 
less likely to be treated on INSTIs. Patients at a higher SES status were more likely on 
INSTIs; in comparison, those at a lower SES were more likely to be on PI-based regimens. 
Patients initiated with unboosted PIs had the lowest mean level of viral load, followed by 
NNRTIs, INSTIs, and boosted PIs. Patients initiated with INSTIs had the highest mean 
level of CD4 counts, followed by NNRTIs, unboosted PIs, and boosted PIs. Patients 
initiated with boosted PIs had a higher proportion of AIDS conditions and opportunistic 
infections than patients on the other regimens. In comparison, patient on INSTIs had less 
severe HIV disease. No patients on PI-based regimens were treated on a single pill of 
ARTs. About 49.7% and 40.9% patients were on a single pill of NNRTI- and INSTI-based 
regimens, respectively. Patients on unboosted PIs had the least comorbid conditions, while 
patients on INSTIs had the most. A detailed comparison is included in Table 5.3. 
 
5.1.3 Patients’ Refill Pattern 
 There were 1,678 (16.3%) and 504 (4.9%) patients who did not have a second fill 




discontinued the initiated regimen in 60 days since the index date is displayed in Figure 
5.2. Patients initiated on unboosted PIs had the highest discontinuation rate of 20.9%, 
compared to boosted PIs of 17.4%, NNRTIs of 15.9%, and INSTIs of 10.1%. 
There were 8,596 patients who did not discontinue the ARTs within 60 days with 
the mean of 29.6±9.7 days for days gap between the first and second fill of base agent. 
Among them, 5,469 (63.6%) patients had second fill within 30 days with the mean of 
23.8±4.5 days for days gap.  
Patients initiated with unboosted PIs had the lowest initial coverage ratio with 
ICRBA of 0.84 and ICRCR of 0.83. Patients initiated with INSTIs had the highest initial 
coverage with ICRBA of 0.90 and ICRCR of 0.89. The detailed results may be found in 
Table 5.4. More than 50% of patients had both ICRBA and ICRCR ≥95% across all the 
regimens. However, there was still a proportion of patients with a very low level of ICRBA 
and ICRCR at <65%, with the proportion range of 14.7% to 28.5%. 
A total of 1,502 (14.6%) patients switched their initiated regimen in one year since 
the index date. The switching rate distribution across the initiated regimens is shown in 
Figure 5.3. About 25.8% patients initiated on unboosted PIs switched to another regimen 
category, followed by 19.2% for boosted PIs, 12.0% for NNRTIs, and 7.1% for INSTIs. 
The days between the index date and the date when the switching occurred across 
the initiated regimens were also calculated (Figure 5.4 and Table 5.5). The distribution of 
days is similar among the regimens with the range for means of 162 to 165 days. When 
comparing the median days, patients initiated boosted PIs switched earlier than other 
regimens, then NNRTIs, unboosted PIs, and INSTIs. 




boosted PIs or NNRTIs; patients initiated with boosted PIs primarily switched to unboosted 
PIs or NNRTIs, and a small proportion switched to INSTI; patients initiated with NNRTIs 
primarily switched to boosted PIs, and a small proportion switched to unboosted PIs or 
INSTIs; patients initiated with INSTIs primarily switched to NNRTIs or boosted PIs. 
Across all initiated regimens, a few patients switched to a regimen composed of two base 
agents. 
 
5.1.4 Thereafter One-Year Adherence 
 Patients were censored when they switched their initiated regimens. There were 
171 patients who switched regimen on the second fill, so they were excluded for calculating 
thereafter one-year PDC. Similar to the pattern for ICRs, patients on INSTIs had the highest 
PDCBA and PDCCR, followed by NNRTI, boosted PI, and unboosted PI. The results are 
shown in Table 5.6. 
 
5.2 Results for Aim 2 
5.2.1 HIV Health Care Utilization 
 The mean viral load monitoring frequency in one year after the index date was 
about 3.3 ± 1.8, whereas the mean CD4 count monitoring frequency was about 2.5 ± 2.0. 
Patients’ HIV office visits were about 7.9 ± 6.9 times on the average in one year after the 
index date. About 21.6% patients were hospitalized during one year, with the mean length 
of stay about 20.2 days. The Box and Whisker Plots for distribution of viral load monitoring 
frequency, CD4 count test frequency, HIV office visits, and LOS between subgroups by 




across these subgroups for each health care utilization variable. 
 
5.3 Results for Aim 3 
5.3.1 Relationship between ICRs and PDCs 
 The correlation between initial coverage ratio of base agent and of complete 
regimen was very strong, with the correlation estimate in the range of 0.92–0.96 for various 
initiated regimens. However, the correlations between ICRs and thereafter one-year PDCs 
were medium with the estimate in the range of 0.54–0.63. The correlation estimates are 
included in Tables 5.7 and 5.8. 
Patients on unboosted PIs were more likely to move to a lower adherence level than 
the others. In comparison, patients on INSTIs were more likely to move to a higher 
adherence level than the others. The patterns of patients changing adherence level is shown 
in Table 5.9 and Figure 5.11. The Kappa coefficients shown in Table 5.10 were also 
calculated to estimate the inter-rater agreements between initial coverage ratio of base 
agent and thereafter one-year PDC of complete regimen based on the categories classified 
in Figure 5.11. The Kappa coefficients indicated a fair strength of the agreements, since all 
coefficients were in the range of 0.21-0.40.85 
 
5.4 Results for Aim 4 
5.4.1 Patient Characteristics Comparison at  
Different Adherence Level 
 
 Patient characteristics at different adherence level were calculated for each initiated 
regimen category (Tables 5.11-5.14). They consistently show that the patients most likely 




load, and higher CD4 counts for all initiated regimens. For other characteristics, patients 
with poor adherence and treated with unboosted PIs were those who were younger, male, 
had less severe HIV conditions, and less comorbidity; patients with poor adherence and 
treated with boosted PIs were those who were older, female, had more severe HIV 
conditions, and less comorbidity; patients with poor adherence and treated with NNRTIs 
were those who were older, female, with more severe HIV conditions, and more 
comorbidity; patients with poor adherence and treated with INSTIs were those who were 
younger, female, with less severe HIV conditions, and less comorbid. 
 
5.4.2 Patients Characteristics Comparison  
on Outcome Missing 
 
 There were 5,955 (58.0%) patients who did not have records for virologic outcomes 
within thirty to 60 days of the index. We compared them to patients who did have virologic 
outcomes. We find that patients with missing outcomes were those who were younger, 
African-American, at lower baseline viral load and higher baseline CD4 counts, treated on 
PIs, healthier, and at lower adherence level. The results are shown in Table 5.15. 
 
5.4.3 Missing Outcome Imputation 
 In order to avoid selection bias, both patients with and without outcomes in the 
study were included. The outcome for patients who had missing value were imputed. The 
data distributions for viral load in log10 were also compared before and after imputation 
for each specific regimen category as shown in the Figure 5.12. The outcome distribution 
before and after imputation are very similar for each specific regimen category. 




before and after imputation (Figure 5.13). The distributions were based on crude estimates 
without controlling patient characteristics. Due to this reason, although the overall trend 
was that decreased adherence is associated with decreased viral suppression rate, the viral 
suppression rate was waving. In general, patients on INSTIs had the highest viral 
suppression rate, followed by patients on NNRTI, unboosted PI, and boosted PIs. 
Patients were divided into four groups: Group 1—patients who had both second fill 
within 60 days and viral load test within 30–60 days; Group 2—patients who had only 
second fill within 60 days but no viral load test within 30–60 days; Group 3—patients who 
had viral load test within 30–60 days but no only second fill within 60 days; and Group 
4—patients who neither had second fill within 60 days nor had viral load within 30–60 
days. Since Group 2 and Group 4 had missing virologic outcome, the viral suppression rate 
was based on imputed date for these two groups. The viral suppression rate for Group 2 
and Group 4 was observed to be lower than that for Group 1 and Group 3, respectively, 
except for patients on INSTIs. This might be caused by the fairly small sample size in 
Group 2 for patients on INSTIs (Figure 5.14). 
 
5.4.4 Results Based on Adherence  
as Dichotomous Variable 
 
 An IPTW approach to create pseudo-populations was used to remove biases caused 
by the confounders based on data for each specific regimen category. The absolute 
standardized differences (ASD) for each confounder was compared before and after 
weighting data. As shown in Figure 5.15, all confounders became balanced after the IPTW 
was applied to each specific regimen model, except for INSTIs data, where the ASD for 




 Based on the weighted data, viral suppression rate was estimated for patients who 
were adherent vs. nonadherent. The results are displayed in Figure 5.16. Across all 
regimens, regardless of selected cutoff to define adherence, the viral suppression rate 
among patients at adherence level above the cutoff was similar. For example, viral 
suppression rate among patients who were adherent to unboosted PIs was estimated to be 
15.0–16.5%, with 12.5–13.4% for boosted PIs, 21.2–21.8% for NNRTIs, and 50.4–51.4% 
for INSTIs. However, when the viral suppression rate difference between adherent patients 
vs. nonadherent patients was compared, the 85% cutoff could be meaningful for other 
cutoffs among patients on unboosted PIs, since the cutoff lower than 85% did not much 
change the viral suppression rate for nonadherent patients. But for other regimens, the 
change of viral suppression rate among nonadherent patients by changing cutoff was 
somewhat linearly associated. Interestingly, although adherent patients on unboosted PIs 
and boosted PIs had very similar viral suppression rate, the nonadherent patients on boosted 
PIs had better outcome than those on unboosted PIs. In comparison, patients on INSTIs 
had the best viral suppression rate regardless of adherence level, and patients on NNRTIs 
could also achieve better viral suppression rate than patients on PIs. 
In the MSM models, adherence had the biggest effect on viral suppression among 
patients on unboosted PIs, followed by boosted PIs, INSTIs, and NNRTIs. The results are 
shown in Table 5.16. For example, among pseudo-population initiated with unboosted PIs, 
patients with initial coverage ratio of ≥ 95% were 3 times (calculated as 1/0.33=3) more 
likely to achieve viral suppression in thirty to 60 days than those with coverage ratio of 
<95%; patients with initial coverage ratio of ≥ 75% were 5.6 times (calculated as 




coverage ratio of <75%.  In comparison, among pseudo-population initiated with INSTIs, 
patients with initial coverage ratio of ≥ 95% were 2.3 times (calculated as 1/0.44=2.3) more 
likely to achieve viral suppression in thirty to 60 days than those with coverage ratio of 
<95%; those with initial coverage ratio of ≥ 75% were 3.8 times (calculated as 1/0.26=3.8) 
more likely to achieve viral suppression in thirty to 60 days than those with coverage ratio 
of <75%. 
 
5.4.5 Results Based on Adherence  
as Multilevel Variable 
 
 The ASDs for each confounder before and after weighting data by comparing 
patients at adherence 75-<95% vs. ≥95% and <75% vs. ≥95% are shown in Figure 5.17. 
The confounders become balanced after IPTW weighting, except for both comparisons for 
INSTIs and adherence <75% vs. ≥95% comparison for unboosted PIs. 
In the MSM models, adherence had the biggest effect on viral suppression among 
patients on PI-based regimens. The results are shown in Table 5.17. Regardless of regimen, 
adherence at 75-<95% did not have a statistically significant effect on viral suppression 
rate compared to adherence at ≥95%; however, these differences might still be clinically 
significant. For example, among pseudo-population initiated with unboosted PIs, patients 
with initial coverage ratio of ≥ 95% were 1.6 times (calculated as 1/0.63=1.6) more likely 
to achieve viral suppression in thirty to 60 days than those with coverage ratio of 75-<95%; 
patients with initial coverage ratio of ≥ 95% were 7.7 times (calculated as 1/0.13=7.7) more 
likely to achieve viral suppression in thirty to 60 days than those with coverage ratio of 
<75%.  In comparison, among pseudo-population initiated with INSTIs, patients with 




achieve viral suppression in thirty to 60 days than those with coverage ratio of 75-<95%; 
those with initial coverage ratio of ≥ 95% were 4 times (calculated as 1/0.25=4) more likely 
to achieve viral suppression in thirty to 60 days than those with coverage ratio of <75%. 
 
5.4.6 Sensitivity Analysis 
Viral suppression rate of patients at different adherence levels were compared 
between various regimens in Figure 5.18. Patients with adherence ≥95% to INSTIs had the 
highest rate of suppression (50.9%), followed by 21.3% for NNRTIs, 16.3% for unboosted 
PI, and 13.2% for boosted PI. When viral suppression rate of patients at adherence 75–<95% 
and ≥95% were compared, the viral suppression rate dropped by 33.1%, 33.3%, 11.3%, 
and 5.8% for unboosted PIs, boosted PIs, NNRTIs, and INSTIs, respectively. INSTIs 
performed best, because patients with adherence <75% still had a viral suppression rate of 
20.7%. 
Sensitivity analyses were also conducted using the following methods: 1) analysis 
based on patients who did not have missing virologic outcomes; and 2) analysis based on 
using viral load <200 and <400 copies/mL as the outcome, respectively. The results are 




Table 5.1 Patient Baseline Characteristics among HIV Treatment-Naïve Veterans 
  Mean/N SD/% 
Demographics 
Age 47.3 10.9 
18–35 years old 1571 15.3% 
36–50 years old 4605 44.8% 
51–65 years old 3672 35.7% 
>65 years old 426 4.1% 
Male 9921 96.6% 
Race/Ethnicity 
White 2972 28.9% 
African-American 5684 55.3% 
Hispanic 664 6.5% 
Others 119 1.2% 
Unknown 835 8.1% 
Social Economic Status (Low to High) 
1st Quartile 2290 22.3% 
2nd Quartile 2264 22.0% 
3rd Quartile 2276 22.2% 
4th Quartile 2278 22.2% 
Unknown 1166 11.3% 
Baseline Labs 
Viral Load (1000 copies/mm3) 176.5 520.1 
<10,000  2032 19.8% 
10,000–<50,000 2683 26.1% 
50,000–<100,000 1791 17.4% 
100,000–<500,000 2849 27.7% 
≥500,000 919 8.9% 
CD4 Counts (cells/mm3) 266.7 212.5 
<200 3244 31.6% 
200–499 3495 34.0% 
≥500 954 9.3% 
Unknown 2581 25.1% 
Disease Severity 
AIDS 1814 17.7% 
Opportunistic Infection 2598 25.3% 
Initiated Regimen 
Regimen 
Unboosted PI 976 9.5% 
Boosted PI 2291 22.3% 
NNRTI 6374 62.0% 
INSTI 633 6.2% 





Table 5.2 Patient Baseline Comorbidities among HIV Treatment-Naïve Veterans 
   Mean/N SD/% 
Deyo-adapted Charlson Comorbid Index 2.2 3.0 
Deyo-adapted CCI=0 4540 44.2% 
Deyo-adapted CCI=1 or 2 2788 27.1% 
Deyo-adapted CCI≥3 2946 28.7% 
Comorbid Conditions 
Hepatitis B 726 7.1% 
Hepatitis C 1913 18.6% 
Alcohol Abuse 3043 29.6% 
Drug Abuse 4997 48.6% 
Depression 1782 17.3% 
Schizophrenic Disorder 575 5.6% 
Psychotic 556 5.4% 
Cancer 1167 11.4% 
Cardiac Arrhythmias 312 3.0% 
Diabetes 874 8.5% 
Hypertension 2941 28.6% 
Hyperlipidemia 1630 15.9% 
Ischemic Heart Disease 3092 30.1% 
Cardiac Insufficiency 303 2.9% 
Heart Valve Disease 102 1.0% 
Cerebrovascular Disease 256 2.5% 
COPD 589 5.7% 
Osteoarthritis 1155 11.2% 
Chronic Anemias 468 4.6% 















NNRTI (N=6,374) INSTI (N=633) 
P-value 
Mean/N SD/% Mean/N SD/% Mean/N SD/% Mean/N SD/% 
Age 46.5 9 47.9 10.5 47.3 11 47 13.2 0.0038 
18–35 years old 105 10.8% 306 13.4% 1008 15.8% 152 24.0% 
<0.0001 
36–50 years old 561 57.5% 996 43.5% 2833 44.4% 215 34.0% 
51–65 years old 290 29.7% 910 39.7% 2250 35.3% 222 35.1% 
>65 years old 20 2.0% 79 3.4% 283 4.4% 44 7.0% 
Male 957 98.1% 2213 96.6% 6151 96.5% 600 94.8% 0.0055 
Race/Ethnicit  White 261 26.7% 647 28.2% 1855 29.1% 209 33.0% 
0.0187 
African-American 534 54.7% 1274 55.6% 3549 55.7% 327 51.7% 
Hispanic 70 7.2% 136 5.9% 413 6.5% 45 7.1% 
Others 11 1.1% 33 1.4% 64 1.0% 11 1.7% 
Unknown 100 10.2% 201 8.8% 493 7.7% 41 6.5% 
SES         1st Quartile 228 23.4% 526 23.0% 1412 22.2% 124 19.6% 
0.0019 
2nd Quartile 217 22.2% 503 22.0% 1389 21.8% 155 24.5% 
3rd Quartile 198 20.3% 484 21.1% 1431 22.5% 163 25.8% 
4th Quartile 199 20.4% 494 21.6% 1440 22.6% 145 22.9% 
Unknown 134 13.7% 284 12.4% 702 11.0% 46 7.3% 
Viral Load (1000 
copies/mm3) 
140.9 211.7 225.8 601.1 159.5 483.2 223.8 804.7 <0.0001 
<10,000  210 21.5% 399 17.4% 1284 20.1% 139 22.0% 
<0.0001 
10,000–<50,000 233 23.9% 531 23.2% 1724 27.0% 195 30.8% 
50,000–<100,000 190 19.5% 354 15.5% 1151 18.1% 96 15.2% 
100,000–<500,000 246 25.2% 726 31.7% 1723 27.0% 154 24.3% 












Boosted PI  
(N=2,291) 
NNRTI (N=6,374) INSTI (N=633) P-value 
Mean/N SD/% Mean/N SD/% Mean/N SD/% Mean/N SD/%  
CD4 Counts 
(cells/mm3) 
244 211.2 229.7 208.2 272.1 204.8 371.9 259.7 <0.0001 
<200 358 36.7% 855 37.3% 1899 29.8% 132 20.9% 
<0.0001 
200–499 288 29.5% 614 26.8% 2368 37.2% 225 35.5% 
≥500 83 8.5% 163 7.1% 580 9.1% 128 20.2% 
Unknown 247 25.3% 659 28.8% 1527 24.0% 148 23.4% 
AIDS 153 15.7% 448 19.6% 1100 17.3% 113 17.9% 0.0290 
Opportunistic 
Infection 
225 23.1% 662 28.9% 1592 25.0% 119 18.8% <0.0001 
All agents in a 
single pill 
0 0.0% 0 0.0% 3168 49.7% 259 40.9% <0.0001 
Deyo-adapted CCI 1.7 2.7 2.4 3.2 2.1 2.9 2.6 3.3 <0.0001 
Hepatitis B 56 5.7% 162 7.1% 474 7.4% 34 5.4% 0.0813 
Hepatitis C 198 20.3% 494 21.6% 1134 17.8% 87 13.7% <0.0001 
Alcohol Abuse 240 24.6% 739 32.3% 1858 29.1% 206 32.5% <0.0001 
Drug Abuse 388 39.8% 1194 52.1% 3084 48.4% 331 52.3% <0.0001 
Depression 127 13.0% 471 20.6% 1008 15.8% 176 27.8% <0.0001 
Diabetes 60 6.1% 175 7.6% 564 8.8% 75 11.8% 0.0002 
Hypertension 166 17.0% 656 28.6% 1880 29.5% 239 37.8% <0.0001 
Hyperlipidemia 46 4.7% 320 14.0% 1080 16.9% 184 29.1% <0.0001 
Ischemic Heart 
Disease 







Table 5.4 Initial Coverage Ratio among Treatment-Naïve Patients 
 Unboosted PI (N=976) Boosted PI (N=2,291) NNRTI (N=6,374) INSTI (N=633) 
Mean/N SD/% Mean/N SD/% Mean/N SD/% Mean/N SD/% 
ICR of Base Agent 0.84 0.20 0.86 0.19 0.87 0.19 0.90 0.17 
50–64% 264 27.1% 506 22.1% 1301 20.4% 93 14.7% 
65–79% 66 6.8% 174 7.6% 470 7.4% 38 6.0% 
80–94% 141 14.5% 256 11.2% 758 11.9% 77 12.2% 
≥95% 505 51.7% 1335 59.1% 3845 60.3% 425 67.1% 
ICR of Complete 
Regimen 
0.83 0.21 0.85 0.21 0.86 0.20 0.89 0.18 
<50% 22 2.3% 48 2.1% 56 0.9% 9 1.4% 
50–64% 256 26.2% 487 21.3% 1290 20.2% 92 14.5% 
65–79% 62 6.4% 180 7.9% 472 7.4% 36 5.7% 
80–94% 143 14.7% 256 11.2% 754 11.8% 81 12.8% 






Table 5.5 Days Switch among Patients Who Switched Initiated Regimen 
First Regimen N Mean Days (SD) Median Days 
Unboosted PI 252 165 (101) 160.5 
Boosted PI 441 162 (98) 149 
NNRTI 764 169 (100) 155 









Table 5.6 Thereafter One-Year Proportion of Days Covered among Treatment-Naïve Patients 
  Unboosted PI (N=945) Boosted PI (N=2,233) NNRTI (N=6,295) INSTI (N=630) 
P-value 
Mean/N SD/% Mean/N SD/% Mean/N SD/% Mean/N SD/% 
One-Year PDC (Base 
Agent) 
0.63 0.34 0.71 0.33 0.74 0.32 0.80 0.28 <0.0001 
<50% 331 35.0% 558 25.0% 1424 22.6% 102 16.2% 
 
<0.0001 
50–64% 90 9.5% 206 9.2% 409 6.5% 37 5.9% 
65–79% 110 11.6% 205 9.2% 607 9.6% 49 7.8% 
80–94% 170 18.0% 456 20.4% 1240 19.7% 145 23.0% 
≥95% 244 25.8% 808 36.2% 2615 41.5% 297 47.1% 
One-Year PDC 
(Complete Regimen) 
0.60 0.34 0.69 0.33 0.73 0.33 0.79 0.29 <0.0001 
<50% 358 37.9% 624 27.9% 1522 24.2% 111 17.6% 
<0.0001 
50–64% 119 12.6% 211 9.5% 449 7.1% 37 5.9% 
65–79% 106 11.2% 224 10.0% 614 9.8% 52 8.3% 
80–94% 162 17.1% 456 20.4% 1243 19.8% 146 23.2% 





Table 5.7 Pearson Correlations between Initial Coverage Ratio of Base Agent and Initial 
Coverage Ratio of Complete Regimen 
 
First Regimen Pearson Correlation 
Initial Coverage Ratio 
(Complete Regimen) 
Unboosted PI Initial Coverage Ratio (Base Agent) 0.95 
Boosted PI Initial Coverage Ratio (Base Agent) 0.92 
NNRTI Initial Coverage Ratio (Base Agent) 0.96 







Table 5.8 Pearson Correlations between Initial Coverage Ratio and  
Thereafter One-Year Proportion of Days Covered 
 
First Regimen Pearson Correlation 
Thereafter One-














































Table 5.9 Relationship between Initial Coverage Ratio and  










Unboosted PI Boosted PI NNRTI INSTI 
≥95% 
≥95% 32.3% 45.8% 53.8% 57.6% 
75–<95% 23.7% 26.7% 24.1% 26.8% 
<75% 44.0% 27.5% 22.2% 15.7% 
75–<95% 
≥95% 14.6% 21.4% 30.0% 31.1% 
75–<95% 30.3% 27.9% 29.9% 35.6% 
<75% 55.2% 50.8% 40.0% 33.3% 
<75% 
≥95% 5.4% 6.8% 9.1% 13.3% 
75–<95% 9.4% 11.7% 16.8% 18.0% 







Table 5.10 Inter-Rater Agreement between Initial Coverage Ratio of Base Agent and 
Thereafter One-Year PDC of Complete Regimen 
 
Initiated Regimen Kappa Coefficient 95% Confidence Interval 
Unboosted PI 0.26 0.23-0.29 
Boosted PI 0.31 0.29-0.34 
NNRTI 0.33 0.31-0.35 








Table 5.11 Baseline Characteristics at Different Adherence among Patient on Unboosted PIs 
  
  
Patients at initial coverage 
ratio of complete regimen ≥ 
95% (N=493)  
Patients at initial coverage 
ratio of complete regimen 
75–<95% (N=166)  
Patients at initial coverage 
ratio of complete regimen 
<75% (N=328)  
Mean/N SD/% Mean/N SD/% Mean/N SD/% 
Age 46.7 9.1 46.6 8.3 46.1 9.2 
18–35 years old 47 9.8% 19 11.4% 39 11.9% 
36–50 years old 281 58.3% 87 52.4% 193 58.8% 
51–65 years old 142 29.5% 59 35.5% 89 27.1% 
>65 years old 12 2.5% 1 0.6% 7 2.1% 
Male 470 97.5% 164 98.8% 323 98.5% 
Race/Ethnicity                           White 156 32.4% 41 24.7% 64 19.5% 
African-American 249 51.7% 98 59.0% 187 57.0% 
Hispanic 21 4.4% 13 7.8% 36 11.0% 
Others 5 1.0% 3 1.8% 3 0.9% 
Unknown 51 10.6% 11 6.6% 38 11.6% 
SES                                   1st Quartile 107 22.2% 40 24.1% 81 24.7% 
2nd Quartile 111 23.0% 32 19.3% 74 22.6% 
3rd Quartile 99 20.5% 38 22.9% 61 18.6% 
4th Quartile 103 21.4% 33 19.9% 63 19.2% 
Unknown 62 12.9% 23 13.9% 49 14.9% 
Viral Load (1000 copies/mm3) 151.9 222.9 155.3 221.1 117.5 187.1 
<10,000  91 18.9% 38 22.9% 81 24.7% 
10,000–<50,000 105 21.8% 43 25.9% 85 25.9% 
50,000–<100,000 104 21.6% 20 12.0% 66 20.1% 
100,000–<500,000 128 26.6% 45 27.1% 73 22.3% 
≥500,000 54 11.2% 20 12.0% 23 7.0% 
  





Table 5.11 Continued 
  
  
Patients at initial coverage 
ratio of complete regimen ≥ 
95% (N=493)  
Patients at initial coverage 
ratio of complete regimen 
75–<95% (N=166) 
Patients at initial coverage 
ratio of complete regimen 
<75% (N=328) 
Mean/N SD/% Mean/N SD/% Mean/N SD/% 
CD4 Counts (cells/mm3) 244.9 209.4 219.9 183.3 254.9 226.4 
<200 174 36.1% 62 37.3% 122 37.2% 
200–499 141 29.3% 51 30.7% 96 29.3% 
≥500 40 8.3% 13 7.8% 30 9.1% 
Unknown 127 26.3% 40 24.1% 80 24.4% 
All agents in a single pill 0 0.0% 0 0.0% 0 0.0% 
Deyo-adapted Charlson Comorbid 
Index 
1.7 2.7 1.8 2.9 1.6 2.7 
Deyo-adapted CCI=0 248 51.5% 87 52.4% 180 54.9% 
Deyo-adapted CCI=1 or 2 118 24.5% 39 23.5% 84 25.6% 
Deyo-adapted CCI≥3 116 24.1% 40 24.1% 64 19.5% 
AIDS 79 16.4% 29 17.5% 45 13.7% 









Table 5.12 Baseline Characteristics at Different Adherence among Patient on Boosted PIs 
  
  
Patients at initial coverage 
ratio of complete regimen ≥ 
95% (N=1291)  
Patients at initial coverage 
ratio of complete regimen 
75–<95% (N=327)  
Patients at initial coverage 
ratio of complete regimen 
<75% (N=679)  
Mean/N SD/% Mean/N SD/% Mean/N SD/% 
Age 47.6 10.6 47.9 10.3 48.5 10.3 
18-35 years old 182 14.1% 44 13.5% 80 11.9% 
36-50 years old 586 45.4% 138 42.2% 272 40.4% 
51-65 years old 476 36.9% 136 41.6% 298 44.3% 
>65 years old 47 3.6% 9 2.8% 23 3.4% 
Male 1251 96.9% 316 96.6% 646 96.0% 
Race/Ethnicity                           White 402 31.1% 90 27.5% 155 23.0% 
African-American 671 52.0% 181 55.4% 422 62.7% 
Hispanic 81 6.3% 19 5.8% 36 5.3% 
Others 19 1.5% 7 2.1% 7 1.0% 
Unknown 118 9.1% 30 9.2% 53 7.9% 
SES                                   1st Quartile 275 21.3% 65 19.9% 186 27.6% 
2nd Quartile 281 21.8% 76 23.2% 146 21.7% 
3rd Quartile 277 21.5% 67 20.5% 140 20.8% 
4th Quartile 291 22.5% 73 22.3% 130 19.3% 
Unknown 167 12.9% 46 14.1% 71 10.5% 
Viral Load (1000 copies/mm3) 266.3 727.9 194.4 432.8 163.5 339.9 
<10,000  210 16.3% 62 19.0% 127 18.9% 
10,000–<50,000 286 22.2% 71 21.7% 174 25.9% 
50,000–<100,000 199 15.4% 51 15.6% 104 15.5% 
100,000–<500,000 409 31.7% 107 32.7% 210 31.2% 
≥500,000 187 14.5% 36 11.0% 58 8.6% 
  






Table 5.12 Continued 
  
  
Patients at initial coverage 
ratio of complete regimen ≥ 
95%  
(N=1291)  
Patients at initial coverage 
ratio of complete regimen 
75–<95% (N=327)  
Patients at initial coverage 
ratio of complete regimen 
<75%  
(N=679) 
Mean/N SD/% Mean/N SD/% Mean/N SD/% 
CD4 Counts (cells/mm3) 233.1 216.0 224.6 187.8 254.9 226.4 
<200 471 36.5% 128 39.1% 256 38.0% 
200–499 351 27.2% 94 28.7% 169 25.1% 
≥500 89 6.9% 23 7.0% 51 7.6% 
Unknown 380 29.4% 82 25.1% 197 29.3% 
All agents in a single pill 0 0.0% 0 0.0% 0 0.0% 
Deyo-adapted Charlson Comorbid 
Index 
2.3 3.1 2.4 3.2 2.4 3.3 
Deyo-adapted CCI=0 547 42.4% 134 41.0% 293 43.5% 
Deyo-adapted CCI=1 or 2 347 26.9% 93 28.4% 170 25.3% 
Deyo-adapted CCI≥3 397 30.8% 100 30.6% 210 31.2% 
AIDS 252 19.5% 67 20.5% 129 19.2% 









Table 5.13 Baseline Characteristics at Different Adherence among Patient on NNRTIs 
  
  
Patients at initial coverage 
ratio of complete regimen ≥ 
95% (N=3727)  
Patients at initial coverage 
ratio of complete regimen 
75–<95% (N=912)  
Patients at initial coverage 
ratio of complete regimen 
<75% (N=1735)  
Mean/N SD/% Mean/N SD/% Mean/N SD/% 
Age 47.3 11.2 47.0 11.2 47.4 10.6 
18–35 years old 595 16.0% 156 17.1% 257 14.8% 
36–50 years old 1632 43.8% 404 44.3% 797 45.9% 
51–65 years old 1328 35.6% 309 33.9% 613 35.3% 
>65 years old 172 4.6% 43 4.7% 68 3.9% 
Male 3605 96.8% 877 96.3% 1669 96.2% 
Race/Ethnicity                           White 157 38.6% 27 28.1% 25 19.2% 
African-American 184 45.2% 53 55.2% 90 69.2% 
Hispanic 26 6.4% 9 9.4% 10 7.7% 
Others 10 2.5% 0 0.0% 1 0.8% 
Unknown 30 7.4% 7 7.3% 4 3.1% 
SES                                   1st Quartile 783 21.0% 179 19.6% 450 25.9% 
2nd Quartile 803 21.5% 232 25.4% 354 20.4% 
3rd Quartile 865 23.2% 210 23.0% 356 20.5% 
4th Quartile 888 23.8% 186 20.4% 366 21.1% 
Unknown 388 10.4% 105 11.5% 209 12.0% 
Viral Load (1000 copies/mm3) 172.9 520.4 188.7 656.7 115.1 216.5 
<10,000  684 18.4% 202 22.1% 398 22.9% 
10,000–<50,000 979 26.3% 226 24.8% 519 29.9% 
50,000–<100,000 693 18.6% 153 16.8% 305 17.6% 
100,000–<500,000 1045 28.0% 264 28.9% 414 23.9% 
≥500,000 326 8.7% 67 7.3% 99 5.7% 
  





Table 5.13 Continued 
  
  
Patients at initial coverage 
ratio of complete regimen ≥ 
95% (N=3727)  
Patients at initial coverage 
ratio of complete regimen 
75–<95% (N=912) 
Patients at initial coverage 
ratio of complete regimen 
<75% (N=1735) 
Mean/N SD/% Mean/N SD/% Mean/N SD/% 
CD4 Counts (cells/mm3) 268.9 207.7 277.4 196.9 275.8 202.9 
<200 1122 30.1% 265 29.1% 512 29.5% 
200–499 1353 36.3% 353 38.7% 662 38.2% 
≥500 326 8.7% 89 9.8% 165 9.5% 
Unknown 926 24.8% 205 22.5% 396 22.8% 
All agents in a single pill 1956 52.5% 464 50.9% 748 43.1% 
Deyo-adapted Charlson Comorbid 
Index 
2.1 2.9 2.1 2.9 2.2 3.0 
Deyo-adapted CCI=0 1646 44.2% 406 44.5% 761 43.9% 
Deyo-adapted CCI=1 or 2 1043 28.0% 246 27.0% 465 26.8% 
Deyo-adapted CCI≥3 1038 27.9% 260 28.5% 509 29.3% 
AIDS 629 16.9% 156 17.1% 315 18.2% 
Opportunistic Infection 960 25.8% 216 23.7% 416 24.0% 
  
  





Table 5.14 Baseline Characteristics at Different Adherence among Patient on INSTIs 
  
  
Patients at initial coverage 
ratio of complete regimen ≥ 
95% (N=407)  
Patients at initial coverage 
ratio of complete regimen 
75–<95% (N=96)  
Patients at initial coverage 
ratio of complete regimen 
<75% (N=130)  
Mean/N SD/% Mean/N SD/% Mean/N SD/% 
Age 47.5 13.4 46.3 12.6 46.0 13.0 
18–35 years old 97 23.8% 23 24.0% 32 24.6% 
36–50 years old 131 32.2% 34 35.4% 50 38.5% 
51–65 years old 146 35.9% 34 35.4% 42 32.3% 
>65 years old 33 8.1% 5 5.2% 6 4.6% 
Male 388 95.3% 89 92.7% 123 94.6% 
Race/Ethnicity                           White 157 38.6% 27 28.1% 25 19.2% 
African-American 184 45.2% 53 55.2% 90 69.2% 
Hispanic 26 6.4% 9 9.4% 10 7.7% 
Others 10 2.5% 0 0.0% 1 0.8% 
Unknown 30 7.4% 7 7.3% 4 3.1% 
SES                                   1st Quartile 71 17.4% 20 20.8% 33 25.4% 
2nd Quartile 102 25.1% 21 21.9% 32 24.6% 
3rd Quartile 101 24.8% 28 29.2% 34 26.2% 
4th Quartile 102 25.1% 20 20.8% 23 17.7% 
Unknown 31 7.6% 7 7.3% 8 6.2% 
Viral Load (1000 copies/mm3) 271.6 959.8 111.6 213.7 157.0 467.5 
<10,000  83 20.4% 33 34.4% 23 17.7% 
10,000–<50,000 130 31.9% 21 21.9% 44 33.8% 
50,000–<100,000 62 15.2% 16 16.7% 18 13.8% 
100,000–<500,000 93 22.9% 22 22.9% 39 30.0% 
≥500,000 39 9.6% 4 4.2% 6 4.6% 
  





Table 5.14 Continued 
  
  
Patients at initial coverage 
ratio of complete regimen ≥ 
95% (N=407)  
Patients at initial coverage 
ratio of complete regimen 
75–<95% (N=96) 
Patients at initial coverage 
ratio of complete regimen 
<75% (N=130) 
Mean/N SD/% Mean/N SD/% Mean/N SD/% 
CD4 Counts (cells/mm3) 369.5 254.4 375.5 252.3 376.0 281.8 
<200 86 21.1% 18 18.8% 28 21.5% 
200-499 135 33.2% 40 41.7% 50 38.5% 
≥500 80 19.7% 21 21.9% 27 20.8% 
Unknown 106 26.0% 17 17.7% 25 19.2% 
All agents in a single pill 169 41.5% 31 32.3% 59 45.4% 
Deyo-adapted Charlson Comorbid 
Index 
2.5 3.2 2.5 3.2 2.8 3.5 
Deyo-adapted CCI=0 154 37.8% 39 40.6% 45 34.6% 
Deyo-adapted CCI=1 or 2 118 29.0% 24 25.0% 41 31.5% 
Deyo-adapted CCI≥3 135 33.2% 33 34.4% 44 33.9% 
AIDS 72 17.7% 15 15.6% 26 20.0% 






Table 5.15 Baseline Characteristics and Initial Adherence Comparison between Patients 




Patients with viral 
outcome (N=4,319) 
Patients without viral 
outcome (N=5,955) P-value 
Mean/N SD/% Mean/N SD/% 
Demographics 
Age 47.7 10.8 47.1 10.9 0.0015 
18–35 years old 612 14.2% 959 16.1% 
0.0069 
36–50 years old 1913 44.3% 2692 45.2% 
51–65 years old 1601 37.1% 2071 34.8% 
>65 years old 193 4.5% 233 3.9% 
Male 4176 96.7% 5745 96.5% 0.4735 
Race/Ethnicity 
White 1297 30.0% 1675 28.1% 
0.038 
African-American 2323 53.8% 3361 56.4% 
Hispanic 297 6.9% 367 6.2% 
Others 57 1.3% 62 1.0% 
Unknown 345 8.0% 490 8.2% 
Social Economic Status 
1st Quartile 916 21.2% 1374 23.1% 
0.199 
2nd Quartile 946 21.9% 1318 22.1% 
3rd Quartile 982 22.7% 1294 21.7% 
4th Quartile 977 22.6% 1301 21.8% 
Unknown 498 11.5% 668 11.2% 
Baseline Labs 
Viral Load (1000 
copies/mm3) 
204.6 600.6 156 451.8 <0.0001 
<10,000  740 17.1% 1292 21.7% 
<0.0001 
10,000–<50,000 1096 25.4% 1587 26.6% 
50,000–<100,000 757 17.5% 1034 17.4% 
100,000–<500,000 1273 29.5% 1576 26.5% 
≥500,000 453 10.5% 466 7.8% 
CD4 Counts (cells/mm3) 260.4 210.7 271.4 213.6 0.0252 
<200 1423 32.9% 1821 30.6% 
0.056 
200–499 1461 33.8% 2034 34.2% 
≥500 386 8.9% 568 9.5% 








       
  
 




Pooled Estimate Based on Five Imputed Datasets 











<95% vs. ≥95% 0.39 0.22-0.70 0.33 0.18-0.63 
<90% vs. ≥90% 0.32 0.17-0.61 0.27 0.14-0.54 
<85% vs. ≥85% 0.22 0.07-0.67 0.18 0.05-0.62 
<80% vs. ≥80% 0.21 0.07-0.63 0.18 0.06-0.55 
<75% vs. ≥75% 0.21 0.08-0.56 0.18 0.06-0.51 
Boosted 
PI 
<95% vs. ≥95% 0.42 0.28-0.63 0.40 0.26-0.62 
<90% vs. ≥90% 0.38 0.23-0.62 0.36 0.22-0.60 
<85% vs. ≥85% 0.39 0.25-0.61 0.38 0.24-0.60 
<80% vs. ≥80% 0.34 0.20-0.57 0.34 0.20-0.58 
<75% vs. ≥75% 0.32 0.17-0.58 0.31 0.17-0.58 
NNRTI 
<95% vs. ≥95% 0.55 0.45-0.68 0.50 0.40-0.62 
<90% vs. ≥90% 0.52 0.40-0.68 0.47 0.36-0.63 
<85% vs. ≥85% 0.46 0.33-0.63 0.41 0.29-0.58 
<80% vs. ≥80% 0.45 0.32-0.63 0.40 0.27-0.58 
<75% vs. ≥75% 0.39 0.27-0.57 0.35 0.23-0.54 
INSTI 
<95% vs. ≥95% 0.48 0.34-0.68 0.44 0.31-0.62 
<90% vs. ≥90% 0.41 0.28-0.58 0.37 0.25-0.54 
<85% vs. ≥85% 0.32 0.21-0.50 0.31 0.20-0.50 
<80% vs. ≥80% 0.30 0.19-0.48 0.30 0.18-0.50 







Table 5.17 Multilevel Adherence Effect Estimates on  





Pooled Estimate Based on Five Imputed Datasets 











75-<95% vs. ≥95% 0.79 0.44-1.42 0.63 0.32-1.21 
<75% vs. ≥95% 0.16 0.05-0.53 0.13 0.03-0.50 
Boosted 
PI 
75-<95% vs. ≥95% 0.65 0.41-1.04 0.64 0.41-1.01 
<75% vs. ≥95% 0.29 0.16-0.52 0.28 0.16-0.51 
NNRTI 
75-<95% vs. ≥95% 0.94 0.73-1.20 0.87 0.68-1.10 
<75% vs. ≥95% 0.38 0.26-0.56 0.34 0.22-0.52 
INSTI 
75-<95% vs. ≥95% 0.92 0.55-1.52 0.89 0.52-1.52 






























































Figure 5.6 Viral Load Monitoring Frequency in One Year since Index Date 
  


































Group Sizes: Min n = 633 Max n = 6374


































Group Sizes: Min n = 119 Max n = 5684


































Group Sizes: Min n = 1166 Max n = 2290


































Group Sizes: Min n = 919 Max n = 2849
  









Figure 5.6 Continued 
  


































Group Sizes: Min n = 954 Max n = 3495


































Group Sizes: Min n = 426 Max n = 4605
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Figure 5.7 CD4 Count Test Frequency in One Year since Index Da 
 






































Group Sizes: Min n = 1166 Max n = 2290






































Group Sizes: Min n = 633 Max n = 6374






































Group Sizes: Min n = 919 Max n = 2849






































Group Sizes: Min n = 119 Max n = 5684
  







Figure 5.7 Continued 
  






































Group Sizes: Min n = 954 Max n = 3495






































Group Sizes: Min n = 426 Max n = 4605






































Group Sizes: Min n = 2788 Max n = 4540
  







Figure 5.8 HIV Office Visit Frequency in One Year since Index Date 
  































Group Sizes: Min n = 633 Max n = 6374































Group Sizes: Min n = 119 Max n = 5684































Group Sizes: Min n = 1166 Max n = 2290































Group Sizes: Min n = 919 Max n = 2849
  







Figure 5.8 Continued 
  































Group Sizes: Min n = 426 Max n = 4605































Group Sizes: Min n = 954 Max n = 3495
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Figure 5.9 Length of Stay in One Year since Index Date among All Patients 
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Group Sizes: Min n = 633 Max n = 6374






























Group Sizes: Min n = 919 Max n = 2849






























Group Sizes: Min n = 119 Max n = 5684
  







Figure 5.9 Continued 
  






























Group Sizes: Min n = 426 Max n = 4605






























Group Sizes: Min n = 954 Max n = 3495
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Figure 5.10 Length of Stay in One Year since Index Date among Hospitalized Patients 
  




































Group Sizes: Min n = 330 Max n = 600




































Group Sizes: Min n = 134 Max n = 1356




































Group Sizes: Min n = 257 Max n = 753




































Group Sizes: Min n = 20 Max n = 1361
  












































Group Sizes: Min n = 105 Max n = 1089




































Group Sizes: Min n = 164 Max n = 898










































Figure 5.11 Adherence Change Pattern by Initiated Regimen  
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Figure 5.12 Distribution of Viral Load in Log10 before and after Imputation 
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Viral Load in Log10 Unit
  










Figure 5.12 Continued  
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Viral Suppression Rate With 95% Confidence Interval  
























       
  
 







Figure 5.15 Confounders Comparison before and after Applying IPTW Based on Imputed 





















Pooled Viral Suppression Rate after Weighting IPTW  
























       
  
 







Figure 5.17 Confounders Comparison before and after Applying IPTW Based on Imputed 






       
  
 












       
  
 











       
  
 















Pooled Viral Suppression Rate after Weighting IPTW 




























 This study focused on exploring HIV treatment-naïve veterans’ adherence and 
visits, and monitoring patterns and determining how patients’ initial adherence (measured 
as initial coverage ratio) affected patients’ virologic outcomes that occurred within thirty 
to 60 days since patients initiated ARTs. 
 
6.1 Our Results in the Context of Previous Work 
 The study cohort was relatively young and healthy, and more than 50% were 
African-Americans. About one-third of patients had a high baseline viral load (viral load ≥ 
100,000 copies/mL). One-tenth of patients initiated ARTs with a CD4 count ≥ 500 
cells/mL. This reflects the US guideline’s recommendations that patients should be 
initiated with ARTs once they are diagnosed with HIV regardless of immunosuppressive 
state.5 The cohort had a very high prevalence of drug abuse (48.6%), which was very close 
to the prevalence rate of 50.1% reported in the HIV Cost and Services Utilization Study 
(HCSUS).86 However, the cohort had a higher rate of alcohol abuse than the rate of patients 
who had heavy drinking that was reported in the HCSUS (29.6% vs 18.5%).86 The cohort 
had a higher prevalence of mental disease than the general HIV population. The prevalence 
of schizophrenic disorder, depression, and psychotic disorder was 5.6%, 17.3%, and 5.4% 
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in our cohort compared to 3.0%, 7.5%, and 1.8%, respectively.87 This is consistent with 
the finding that veterans have a higher rate of mental disease than the general population.88 
Noticeably, the cohort had a much higher rate of ischemic heart disease (IHD) than the 
general veterans (30.1% vs. 16.9%).89 The literature indicates higher risk of cardiovascular 
events may be due to interaction between traditional risk factors and HIV infection and 
increased risk of thrombosis caused by endothelial dysfunctional immune 
activation/inflammation.90 Another potential reason is that patients treated with ARTs have 
a higher risk of developing IHD.90 The study could have mistakenly identified treatment-
experienced patients as treatment-naïve patients, but strict inclusion/exclusion criterion 
were developed to make sure these patients were treatment-naïve.  
 The NNRTIs were the most commonly used regimen among the cohort, which 
accounted for about 62.0%, with 22.3% of patients on boosted PIs, 9.5%, of patients on 
unboosted PIs, and about 6.2% of patients on INSTIs. The reason that patients on INSTIs 
had the smallest proportion is because INSTIs were not approved on the market until 2007.5 
The study discovered that patients initiated on unboosted PIs were more likely to be male, 
younger, healthier, and had less severe HIV-related conditions; in comparison, patients 
initiated on INSTIs were more likely to be female, white, with higher baseline viral load, 
and with more comorbid conditions; patients initiated on boosted PIs or NNRTIs were in 
between. This reflects physicians’ prescribing pattern and real practice in the VA setting 
to some degree. As the guidelines suggest, the most INSTI-based regimens are highly 
effective with few adverse effects and less potential for drug-drug interactions. They are 
recommended to most patients. 5 
 The cohort had a high initial coverage ratio with the mean of 0.84–0.90 for base 
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agent and 0.83–0.89 for the complete regimen. Among the cohort, patients initiated on 
INSTIs had the highest coverage. This is because of the superiority of INSTIs in first-line 
HIV therapy in terms of its fewer adverse effects and better tolerance.91 Patients initiated 
on PIs had the lowest coverage. This might be due to the high pill burden and treatment-
associated adverse events.5 Patients on unboosted PI have even lower adherence than those 
on boosted PI. The reason might be that patients on unboosted PI were younger and 
healthier, as patient characteristics were compared across regimens. For the thereafter one-
year adherence, the same pattern was also observed. About 45.1% patient on INSTIs 
showed adherence levels at ≥95%; however, the proportion was only 21.2% for patients on 
unboosted PIs. The mean of thereafter one-year PDC of complete regimen was found to be 
0.60–0.79 for various regimens. This finding is consistent with another adherence study 
among the US veterans treated with ARTs, which reported that the median of first year 
PDC to ARTs was 0.73 with the interquartile range of 0.41–0.97.92 Due to the low genetic 
barrier to drug resistance and the potential for cross-resistance within the NNRTIs, patients 
on NNRTIs had lower thereafter one-year PDC than those on INSTIs. 5 
 Regardless of initiated regimen, patients had a similar frequency of viral load and 
CD4 count monitoring. The mean viral load monitoring frequency in one year after the 
index date was 3.3 ± 1.8; however, the mean CD4 count monitoring frequency was 2.5 ± 
2.0, just a little bit lower than viral load monitoring frequency. Both frequencies were lower 
than what the guidelines suggested. 5 The guidelines recommend to check viral load within 
one month after treatment initiation, every one to two months until viral load is suppressed, 
and then every three to four months in the first two years. They also recommend to check 
CD4 count within three months after treatment, then every three to six months in the first 
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two years. 5 
 Patients’ HIV office visits and length of stay for hospitalization were 7.9 times 
(median: 6 times) and 4.4 days (median: 0 day) on average in the first year after the index 
date. The distribution of both measures was similar across the regimens. Among 2,221 
(21.6%) hospitalized patients, the length of stay was 20.2 days (median: 7 days) on average. 
Although there is no recommended HIV office visit frequency in the first year, the 
guidelines suggest that for frequency of viral load and CD4 count monitoring, patient visits 
for HIV physicians should be around six to seven times in the first year. Due to the limit 
of data that could be obtained, nothing is known about the missed office visits for these 
patients. One study has evidenced that missed office visits would significantly increase 
mortality risk among US population with HIV.93 The hospitalization rate of the present 
cohort is similar to the study of the HIV Research Network (HIVRN) cohort composed of 
adult patients with HIV in the US, which reported a hospitalization rate of 22.2%.94 
However, the mean of total length of stay in one year for the HIVRN cohort who were 
hospitalized was about 12.9–13.9 days during 2000 to 2002, which was shorter than this 
study’s cohort. 94 This might be caused by a proportion of veterans who had extremely long 
length of hospitalization more than 300 days, since the median length of stay for the study 
cohort was only about 7 days. 
 The initial coverage ratio of base agent and complete regimen were highly 
correlated. However, the correlations between initial coverage ratio and thereafter one-year 
PDC were low. One previous study has shown that it is hard to distinguish patients who 
would be not adherent to ARTs based on patients’ baseline characteristics.78 This finding 
further confirms that short-term adherence does not well predict long-term adherence either. 
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The present findings also show interaction between adherence and type of regimens, which 
means ARTs have an influence on long-term adherence. For example, if patients’ initial 
adherence was low and they were also initiated on a PI-based regimen, then patients were 
more likely to be at low adherence; in comparison, if patients’ initial adherence was high 
and they were initiated on NNRTI-based regimen, then patients were more likely to be at 
high adherence. These suggested that regimens’ side effects and barriers to drug resistance 
may influence long-term adherence. 
 Patients who were African-Americans and had a low social economic status, low 
baseline viral load, and high baseline CD4 counts consistently had lower adherence than 
other patients across all regimens. These findings were consistent with the results of other 
published studies. Evidence showed that racial disparities exist in HIV treatment adherence, 
and African-Americans had the lowest adherence of all races, including whites and 
Latinos.95 A meta-analysis study reported that patients who did not perceive their disease 
as severe or as a threat were >1.5 times more likely to be nonadherent.96 The present study 
found that patients who had missing outcomes shared the similar characteristics with 
patients at low adherence levels.  
 In the pseudo-population, regardless of the threshold to define adherent, adherent 
patients had similar viral suppression rates for each regimen category: 15.0–16.5% for 
unboosted PIs, 12.5–13.4% for boosted PIs, 21.2–21.8% for NNRTIs, and 50.4–51.4% for 
INSTIs. However, when the viral suppression rate differences between adherent and 
nonadherent patients using various thresholds were compared, findings were different. It 
seems that the 85% threshold matters for unboosted PIs, since after that, lower adherence 
does not affect the viral suppression rate; but for the other regimens, the relationship 
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between adherence and viral suppression rate of nonadherence has a linear trend. When 
adherence was measured as a categorical variable, medium adherence was found to have 
the biggest effect on viral suppression rates among patients on unboosted PIs, followed 
next by boosted PIs. However, for patients on NNRTIs and INSTIs, there was an almost 
obvious difference in viral suppression rates between patients at medium adherence and at 
high adherence. These findings suggest adherence affected viral suppression rate variously 
by regimen class. For PI-based regimens, medium level adherence would have significant 
effects on viral suppression; but for NNRTI- or INSTI-based regimens, adherence might 
not significantly influence adherence, until adherence is reduced to the lowest level. These 
findings are similar to what was reported in the literature that the 95% threshold might not 
be necessary and adherence works differently on viral suppression rate for various 
regimens.27,29,30,37,73,74,97 However, all of the current findings suggest a 95% threshold for 
adherence is not necessary. Due to the limited sample size, dividing adherence into more 
than 3 levels could cause positivity issue (not enough sample size) to estimate adherence 
effect; therefore, an adherence effect could not be estimated when adherence was evenly 
divided into narrower adherence categories. 
 In the MSM models, regardless of threshold to define adherence, adherent patients 
had significantly higher viral suppression rate than nonadherent patients. Patients at 
medium adherence had a significantly reduced rate of viral suppression for PI-based 
regimens, but not for NNRTI- or INSTI-based regimens. Across all regimens, low 
adherence was more consistently associated with a reduced viral suppression rate than high 
adherence.  
 Interestingly, patients on INSTIs consistently had the highest viral suppression rate 
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no matter what adherence level patients were at, followed by the patients on NNRTIs, and 
then those on PIs. For example, patients on INSTIs with adherence <75% still had a viral 
suppression rate of 20.7%, which was the same as the rate for patients on NNRTIs with 
adherence ≥95% and higher than the rate for the patients on PIs with adherence ≥95%. 
However, this may not indicate that INSTIs would be more potent than PIs and NNRTIs. 
It is because the patients initiated with different regimens had different characteristics, 
which made the adherence effects not comparable across the regimen categories. 
  
6.2 Strengths 
This study helped to understand how the HIV treatment-initiated veterans were 
treated and monitored, as well as how they used the health care through the VHA system 
within one year after treatment initiation. 
Multiple methods to measure patient adherence were applied, including coverage 
ratio and PDC for both a base agent and a complete regimen.  
The study also added the evidence that it would be hard to predict patients who 
would potentially have poor adherence in the future just according to the patients’ initial 
adherence, since the correlation between these two measures is so weak. 
Moreover, our study applied an IPTW approach, a causal inference method to 
address confounding bias and to identify the causal effects of initial adherence to different 
HIV regimens on virologic outcomes among veterans with HIV-1. The present was a 
comprehensive study that investigated the various first-line regimens, including 
unboosted/boosted PI-, NNRTI-, and INSTI-based regimens. 
Different from previous studies, adherence effects were estimated via traditional 
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relative risk estimate (i.e., odds ratio); figures were also created to display viral suppression 
rates based on a pseudo-population after balancing confounders between comparison 
groups. 
Sensitivity analyses were also conducted to assess the robustness of study results. 
For example, multiple methods were used to define viral suppression, including definition 
by the guidelines or viral load <50 copies/mL, and also some other thresholds to define a 
good virologic outcome, i.e., viral load <200 copies/mL or viral load <400 copies/mL. As 
for the initial adherence, different methods were also used to measure it, including 
calculating it as a continuous variable, dichotomizing it into a binary variable via selecting 
different thresholds, and categorizing it into a categorical variable with three levels. 
 Finally, this study did not simply exclude patients who had missing outcomes 
similar to what previous studies have done, but applied imputation techniques to impute 
the outcome. The purpose of doing this was to avoid selection bias, which was especially 
true if patients who had missing outcomes were more likely to be those who had poor 
adherence. This has been confirmed when patient characteristics were compared between 
patients with or without missing outcomes. 
 
6.3 Limitations 
Since this is a retrospective study based on an existing database, some limitations 
are unavoidable. The first limitation is related to the inclusion/exclusion criteria. Although 
rules were made to maximally exclude patients that would be treatment-experienced, it is 
still possible to misclassify patients.  
Second, adherence was calculated according to refill records, which might not 
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really reflect patient adherence behavior. And although unlikely, there is a possibility that 
patients obtained medications outside the VHA system.  
Third, an assumption was made to calculate initial adherence. If there was no 
second fill of base agent within 60 days, patients were assumed to have discontinued the 
regimen, resulting in a calculation of patients’ initial coverage ratio of base agent as 0.5. 
This is the conservative way to calculate adherence, since these patients are highly likely 
to have even lower adherence or do not take ARTs at all.  
Forth, this study is a short-term study focused on exploring the causal effects of 
initial adherence on virologic outcomes that occurred during thirty to 60 days after 
treatment initiation. So, findings might not be generalizable to the long-term effect of 
adherence, or to treatment-experienced patients. Additionally, the study results might not 
be generalizable to a more general population outside the VHA system. 
Fifth, an IPTW approach was applied to address confounding bias. This technique 
requires three assumptions: consistency (an individual potential outcome under the 
observed exposure history is precisely the observed outcome), positivity (nonzero 
probability of receiving every level of exposure for every combination of values of 
exposure and covariates), and exchangeability (no unmeasured confounders).98 However, 
some assumptions are untestable. For example, if there are potentially unknown 
confounders, then IPTW could not remove confounding bias, even if the all observed 
confounders become balanced between comparison groups after weighting. Actually, even 
though IPTW weighting was conducted, balance could not be achieved for some specific 
regimens (i.e., INSTI-based regimen) due to limited sample size. This should be kept in 
mind when making decision based on the study results.  
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Sixth, outcomes were imputed for patients who had missing values. The imputed 
value might not be the same as true observations if virologic outcomes were captured 
during that specific time period. However, more than one method to impute data was tried, 
in addition to comparing data before and after imputation to make sure the imputed 
outcomes were as close to the truth as possible. 
Seventh, due to a limited data source, variables could not be captured that were 
related to the present study, such as patients’ medical literacy, missing of scheduled HIV 
office visits, HIV/AIDS-caused hospitalizations, and bio-markers of HIV, or HIV severity 
index. Besides, this study only evaluated the adherence effects on virologic outcome 
without considering time to event. That is because, in this study, time to event depended 
on when the viral loads were measured, which would not reflect the exact time when 
patients achieved viral suppression. 
Eighth, lab data from the VHA contained hundreds and even thousands of different 
lab names for viral load and CD4 count tests. The test values were also not well structured, 
including both text and numeric values. The algorithm that we used might have potentially 
missed some tests or lab values that should have been included. 
Last but not least, we built models for each regimen category, respectively. Patients 
initiated with different regimens might have different characteristics. So the adherence 
effects on viral suppression might not be comparable across regimens.  
 
6.4 Conclusions, Implications, and Future Research  
 In general, the HIV treatment of newly-initiated patients initiating ART were well 
monitored in the first year in terms of viral load and CD4 count test frequency, as well as 
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office visits. The hospitalization rate of the cohort was similar to the estimate of the HIVRN 
cohort composed of adults with HIV in the US, but with longer stays among the 
hospitalized patients in the average, due to a proportion of veterans who had extremely 
long stays. Although the initial coverage ratio of base agent and complete regimen were 
highly correlated, the correlations between initial coverage ratio and thereafter one-year 
PDC were low, which indicated that patients’ long-term adherence could not be predicted 
by their short-term adherence alone. Compared to NNRTI- and PI-based regimens, INSTI-
based regimens were most potent, achieving the highest viral suppression rate, even among 
the patients who had poor adherence. Lower adherence caused lower viral suppression 
rates, with the association differentiated by the regimen. Due to limited sample size in each 
regimen category, classifying adherence level into more than three levels would cause few 
observations in some levels. Although it was still hard to clearly understand if the 
association between adherence and viral suppression was linear, had a threshold 
somewhere, or a combination of both, the present study found that patients on PI-based 
regimens were more likely to fail to achieve viral suppression at a higher adherence 
threshold than other regimens.  
 The study could have many implications. First, although the initial coverage ratio 
could not perfectly predict patients’ long-term adherence, the correlation between them 
was in the range of 0.54–0.63, indicating medium strength. Correlations between the initial 
adherence and thereafter adherence were found to be different depending on which 
regimens that patients were on. All these suggest that it is valuable to include baseline 
adherence and the nature of regimen (i.e., treatment effectiveness, side effects, barrier to 
drug resistance) as the important predictors to predict patients’ long-term adherence.  
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Second, in comparison, patients on PIs are more likely to move to a lower 
adherence category, which suggests more attention should be paid to patients who were 
treated on PIs. Some interventions should be initiated to improve adherence of this group 
specifically.  
Third, the present study does not support the 95% threshold to be as important as 
suggested in the guidelines, since viral suppression rate among patients with adherence 
level of ≥75% was very similar to the rate among those with adherence level of ≥95%. 
Besides, although patients with medium adherence (75-<95%) did not have a significantly 
reduced rate compared to patients with high adherence (≥95%), the differences between 
them were still clinically significant. Therefore, keeping patients’ adherence level as high 
as possible is important to maximize the possibility of achieving viral suppression. 
 There are still many questions that need to be answered in future studies. It remains 
unknown if missing scheduled HIV office visits potentially influences patient virologic 
outcomes. HIV veterans had a longer length of stay, even though the hospitalization rates 
were similar between them and the US general population. That difference should also be 
explored. Further studies should investigate why patients on each specific regimen 
category had a lower adherence, including the reason that patients had a low adherence at 
baseline, and why so many patients who had a high initial adherence eventually moved to 
lower-adherence category. Finding-based interventions should be initiated among these 
patients. Future studies should apply more advanced technology, such as natural language 
process (NLP), to identify HIV labs and their values in medical notes to add more data and 
improve the data accuracy in our study. The present study only explored the effect of initial 
adherence on viral suppression, with the consideration of avoiding time-dependent 
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confounding bias. Futures studies should explore the long-term effect with addressing 
time-dependent confounding bias, or the adherence effect on the time to event, or some 
other outcomes of interest such as immunologic outcomes, viral rebound, hospitalization 
caused by HIV/AIDS, death, drug resistance, or quality of life. More advanced methods 
should be applied to identify the causal effect of continuous adherence or delayed filling 
days on either categorical or continuous outcomes (i.e., viral load or CD4 counts). The 
study censored patients when they switched the initiated regimen. Future studies could 
apply a dynamic treatment regimes approach to understand how the different treatment 
strategy combined with different starting adherence level would influence outcomes. 
Future studies also need to explore the adherence effects among treatment-experienced 
patients.  
 In summary, this study showed how initial adherence differently influenced the 
viral suppression rate across different regimens. No evidence shows 95% adherence 
threshold is necessary. Patients with medium adherence (75-<95%) can achieve viral 
suppression with the rate not statistically significantly different from patients with high 







A.1 Analyses Based on Patients Who Did Not Have Missing Outcomes 
 We only do analysis for dichotomized adherence. The reason that we do not do 
analysis for adherence at three levels is because of positivity issues, since there is a lack of 
observations for some cells. 
 





Figure A.1 Confounders Comparison before and after Applying IPTW Based on 






       
  
 
















Viral Suppression Rate after Weighting IPTW  







Figure A.2 Viral Suppression Rate after Weighting IPTW  



















Viral Suppression Rate after Weighting IPTW  






Figure A.2 Continued 
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A.2 Analyses for Virologic Outcome Defined as Viral Load < 50 Copies/mL, < 200 
Copies/mL, < 400 Copies/mL Based on Imputed Data 
 
Regimen 
Pooled Rate of Viral Load < 50 Copies/mL after Weighting IPTW 







Figure A.3 Rate of Viral Load < 50 Copies/mL by Dichotomized Adherence after 












Pooled Rate of Viral Load < 50 Copies/mL after Weighting IPTW 














Pooled Rate of Viral Load < 200 Copies/mL after Weighting IPTW 







Figure A.4 Rate of Viral Load < 200 Copies/mL by Dichotomized Adherence after 



















Pooled Rate of Viral Load < 200 Copies/mL after Weighting IPTW 















Pooled Rate of Viral Load < 400 Copies/mL after Weighting IPTW 







Figure A.5 Rate of Viral Load < 400 Copies/mL by Dichotomized Adherence after 



















Pooled Rate of Viral Load < 400 Copies/mL after Weighting IPTW 















Pooled Rate of Virologic Outcome by Multilevel Adherence after 







Figure A.6 Rate of Virologic Outcome by Multilevel Adherence after Applying IPTW 













Pooled Rate of Virologic Outcome by Multilevel Adherence after 
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